Substituted fused bicyclic compounds and related methods of treatment

Abstract

The present invention provides compounds useful in the treatment of narcolepsy or cataplegia in a subject in need thereof. Also provided are related pharmaceutical compositions and methods of treating narcolepsy or catapult in a subject in need thereof, comprising administering to the subject a compound or a pharmaceutically acceptable salt or composition thereof.

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 353,998, filed on June 21, 2022. The entire contents of the above-identified application are incorporated herein by reference. Technical Field

[0003] The present invention relates to substituted bicyclic compounds, particularly substituted fused bicyclic compounds having agonist activity. Background Art

[0004] Orexin is a neuropeptide synthesized and released by a subpopulation of neurons in the lateral hypothalamus and its surrounding areas. It consists of two subtypes: orexin A and orexin B. Orexin A and orexin B bind to orexin receptors. Orexin receptors are G protein-coupled receptors that are preferentially expressed in the brain. There are two subtypes of orexin receptors (type 1 and type 2) (Cell, Vol. 92, 573-585, 1998). It is known that the activation of orexin receptors is important for a variety of central nervous system functions, such as maintaining wakefulness, energy homeostasis, reward processing and motivation (Saper et al., TRENDS in Neuroscience 2001; Yamanaka et al., Neuron 2003; Sakurai, Nature Reviews Neuroscience 2014).

[0005] Narcolepsy is a neurological disease that causes excessive daytime sleepiness, sudden muscle paralysis attacks (cataplexy) and disturbed sleep patterns (Mahoney et al., Nature Reviews Neuroscience, 2019). It is known that narcolepsy is caused by the degeneration of orexin neurons. Narcolepsy symptoms can be simulated in transgenic mice designed to degenerate orexin neurons, and orexin peptides can be administered intraventricularly to reverse its symptoms (Proc. Natl. Acad. Sci. USA, Vol. 101, 4649-4654, 2004). Studies on orexin-2 receptor knockout mice have shown that orexin-2 receptors play a priority role in maintaining wakefulness (Cell, Vol. 98, 437-451, 1999, Neuron, Vol. 38, 715-730, 2003). Therefore, orexin-2 receptor agonists may be therapeutic agents for narcolepsy or other disorders exhibiting excessive daytime sleepiness, such as Parkinson's disease (CNS Drugs, Vol. 27, 83-90, 2013; Brain, Vol. 130, 2007, 1586-1595).

[0006] It is assumed that compounds having agonist activity at orexin-2 receptors can be used as novel therapeutic agents for narcolepsy, idiopathic hypersomnia, narcolepsy, sleep apnea syndrome, disturbances of consciousness such as coma, narcolepsy syndrome, hypersomnia syndrome characterized by hypersomnia (e.g., in Parkinson's disease, Guillain-Barre syndrome or Kleine-Levin syndrome), Alzheimer's disease, obesity, insulin resistance syndrome, heart failure, diseases associated with bone loss or sepsis, etc. (Cell Metabolism, Vol. 9, 64-76, 2009; Neuroscience, Vol. 121, 855-863, 2003; Respiration, Vol. 71, 575-579, 2004; Peptides, Vol. 23, 1683-1688, 2002; WO 2015 / 073707; Journal of the American College of Cardiology, Vol. 66, 2015, pages 2522-2533; WO 2015 / 048091; WO 2015 / 147240).

[0007] Some compounds with orexin-2 receptor agonist activity have been reported (U.S. Patent No. 8,258,163; WO2015 / 088000; WO 2014 / 198880; Journal of Medicinal Chemistry, Vol. 58, pages 7931-7937; US20190040010; US20190031611; US ​​20170226137). However, it is believed that these compounds are not satisfactory, for example, in terms of activity, pharmacokinetics, penetration into the brain / central nervous system, or safety, and it is desirable to develop improved compounds with orexin-2 receptor agonist activity. Summary of the invention

[0008] The object of the present invention is to provide a fused bicyclic compound having orexin-2 receptor agonist activity.

[0009] Therefore, in a first aspect, the present invention provides a compound represented by Formula IA or a pharmaceutically acceptable salt thereof:

[0010]

[0011] in:

[0012] Ring A is fused to ring B;

[0013] Ring A is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0014] Ring B is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0015] X is N or CH;

[0016] Y is S(=O)2, C(=O) or S(=O)(=NR e );

[0017] R e Selected from the group consisting of H, C1-C3 alkyl or C3-C5 cycloalkyl;

[0018] E is selected from the group consisting of: NR a R b 、C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl, and C1-C3 alkylene-(5- to 7-membered heteroaryl), wherein the C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10aryl), 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl) is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution;

[0019] R a and R b Each independently selected from the group consisting of H, C1-C3 alkyl, C3-C5 cycloalkyl and 4- to 7-membered heterocyclyl; wherein the C1-C3 alkyl, C3-C5 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxy;

[0020] Or, alternatively, R a and R b Together with the N atom to which they are attached, they form a 4- to 7-membered heterocyclyl or a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , C1-C3 alkyl, C1-C3 alkoxy or C1-C3 alkyl substituted by 1-3 halogens;

[0021] R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 Aryl), C(=O)-(CR c R d ) n -(5- to 10-membered heteroaryl), C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclic group), (CR c R d ) n -(C6-C 10Aryl) and (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 Aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0022] R c and R d Each is independently H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogens or deuterium;

[0023] n is 0, 1, or 2;

[0024] Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium;

[0025] Or, alternatively, R3 and R6 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0026] Or, alternatively, R4 and R5 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0027] m is 0 or 1;

[0028] p is 0, 1, 2, 3 or 4; and

[0029] Each R9 is independently selected from the group consisting of deuterium, halogen, hydroxyl and cyano.

[0030] In one embodiment, provided herein is a compound of Formula IA having the structure of Formula I or a pharmaceutically acceptable salt thereof:

[0031]

[0032] in:

[0033] Ring A is fused to ring B;

[0034] Ring A is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0035] Ring B is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0036] X is N or CH;

[0037] Y is S(=O)2, C(=O) or S(=O)(=NR e );

[0038] R e Selected from the group consisting of H, C1-C3 alkyl or C3-C5 cycloalkyl;

[0039] E is selected from the group consisting of: NR a R b 、C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl, and C1-C3 alkylene-(5- to 7-membered heteroaryl), wherein the C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl) is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution;

[0040] R a and R b Each independently selected from the group consisting of H, C1-C3 alkyl, C3-C5 cycloalkyl and 4- to 7-membered heterocyclyl; wherein the C1-C3 alkyl, C3-C5 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxy;

[0041] Or, alternatively, R a and R b Together with the N atom to which they are attached, they form a 4- to 7-membered heterocyclyl or a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , C1-C3 alkyl, C1-C3 alkoxy or C1-C3 alkyl substituted by 1-3 halogens;

[0042] R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 Aryl), C(=O)-(CR c R d ) n -(5- to 10-membered heteroaryl), C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclic group), (CR c R d ) n -(C6-C 10 Aryl) and (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10Aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0043] R c and R d Each is independently H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogens or deuterium;

[0044] n is 0, 1, or 2;

[0045] Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium;

[0046] Or, alternatively, R3 and R6 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0047] Or, alternatively, R4 and R5 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0048] m is 0 or 1;

[0049] p is 0, 1, 2, 3 or 4; and

[0050] Each R9 is independently selected from the group consisting of deuterium, halogen, hydroxyl and cyano.

[0051] Also provided herein is a pharmaceutical composition comprising a compound of Formula IA or I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0052] In another aspect, provided herein is a method of treating narcolepsy in a subject in need thereof, the method comprising administering to the subject a compound of Formula IA or I, or a pharmaceutically acceptable salt thereof.

[0053] In another aspect, provided herein is a method of treating cataplexy in a subject in need thereof, the method comprising administering to the subject a compound of Formula IA or I, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION

[0054] Provided herein are compounds useful for treating narcolepsy or cataplexy in a subject, for example, a compound of Formula IA or I, or a pharmaceutically acceptable salt thereof.

[0055] In non-limiting aspects, these compounds can modulate orexin-2 receptors. In specific embodiments, provided herein are compounds that are considered orexin-2 agonists. Therefore, in one aspect, provided herein are compounds that can be used to treat narcolepsy in a subject by acting as an agonist of orexin-2 receptors.

[0056] definition

[0057] Listed below are definitions of various terms used to describe the present invention. These definitions apply to the terms as used throughout the specification and claims, unless otherwise limited in specific instances, whether individually or as part of a larger group.

[0058] Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well known and commonly used in the art.

[0059] As used herein, the articles "a" and "an" refer to one or more than one (i.e., at least one) of the grammatical object of the article. For example, "element" means one element or more than one element. Furthermore, the use of the term "including" as well as other forms such as "include," "includes," and "included" is not limiting.

[0060] As used herein, the term "about" will be understood by one of ordinary skill in the art and will vary to some extent depending on the context in which it is used. As used herein, when referring to a measurable value such as an amount, a duration of time, etc., the term "about" is meant to encompass variations of ±20% or ±10%, including ±5%, ±1%, and ±0.1% from the specified value, as such variations are suitable for performing the disclosed methods.

[0061] As used herein, the term “EC 50 ” refers to the concentration of a compound required to achieve 50% of the maximum observed effect of the compound.

[0062] As used herein, the term "agonist" refers to a compound that, when contacted with a target of interest (e.g., orexin-2 receptor), causes an increase in the magnitude of a certain activity or function of the target compared to the magnitude of the activity or function observed in the absence of the agonist.

[0063] The terms "treat," "treated," "treating," or "treatment" include reducing or alleviating at least one symptom associated with or caused by the state, disorder, or disease being treated. In certain embodiments, treatment comprises contacting an effective amount of a compound of the invention for a condition associated with narcolepsy or cataplexy with an orexin-2 receptor.

[0064] As used herein, the term "prevent" or "prevention" means that if a disorder or disease has not occurred, then there is no development, or if a disorder or disease has developed, then there is no further development of the disorder or disease. Also contemplated is the ability of an individual to prevent some or all symptoms associated with a disorder or disease.

[0065] As used herein, the term "patient", "individual" or "subject" refers to a human or non-human mammal. Non-human mammals include, for example, livestock and pets, such as sheep, cattle, pigs, dogs, cats and mice. Preferably, the patient, subject or individual is a human.

[0066] As used herein, the terms "effective amount", "pharmaceutically effective amount" and "therapeutically effective amount" refer to an amount of an agent that is non-toxic but sufficient to provide the desired biological result. The result can be a reduction or alleviation of the signs, symptoms or causes of a disease, or any other desired change in a biological system. The appropriate therapeutic amount in any individual case can be determined by one of ordinary skill in the art using routine experimentation.

[0067] As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compound and is relatively nontoxic, i.e., the material can be administered to a subject without causing adverse biological effects or interacting in a deleterious manner with any component of the composition in which it is contained.

[0068] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of a disclosed compound in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts of the present invention include conventional non-toxic salts of the parent compound, such as conventional non-toxic salts of the parent compound formed from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound containing a basic or acidic moiety by conventional chemical methods. Typically, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of a suitable base or acid in water or in an organic solvent or in a mixture of the two; typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. The phrase "pharmaceutically acceptable salt" is not limited to monosalts or 1:1 salts. For example, "pharmaceutically acceptable salts" also include disalts, such as dihydrochloride. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

[0069] As used herein, the term "composition" or "pharmaceutical composition" refers to a mixture of at least one compound useful in the present invention and a pharmaceutically acceptable carrier. Pharmaceutical compositions facilitate administration of the compound to a patient or subject. There are a variety of techniques for administering compounds in the art, including but not limited to intravenous, oral, aerosol, parenteral, ocular, pulmonary, and topical administration.

[0070] As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or vehicle involved in carrying or transporting a compound useful in the present invention in or to a patient so that the compound can perform its intended function, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent or encapsulating material. Typically, such a construct is carried or transported from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation (including the compounds useful in the present invention) and not harmful to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic compatible substances used in pharmaceutical formulations.

[0071] As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, etc., which are compatible with the activity of the compounds useful in the present invention and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the composition. "Pharmaceutically acceptable carrier" may further include pharmaceutically acceptable salts of the compounds useful in the present invention. Other additional ingredients that may be included in the pharmaceutical compositions for practicing the present invention are known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which are incorporated herein by reference.

[0072] As used herein, unless otherwise indicated, the term "alkyl", by itself or as part of another substituent, means a straight or branched chain hydrocarbon (i.e., C 1-6 Alkyl means an alkyl group having one to six carbon atoms), and includes straight and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl and hexyl. Other examples of C1-C6-alkyl groups include ethyl, methyl, isopropyl, isobutyl, n-pentyl and n-hexyl.

[0073] As used herein, unless otherwise stated, the term "halo" or "halogen" alone or as part of another substituent means a fluorine, chlorine, bromine or iodine atom, preferably fluorine, chlorine or bromine, more preferably fluorine or chlorine.

[0074] As used herein, the term "alkylene" refers to a divalent aliphatic hydrocarbon group, for example, having 1 to 4 carbon atoms, which is straight or branched. This term includes, for example, methylene (-CH2-), ethylene (-CH2CH2-), n-propylene (-CH2CH2CH2-), isopropylene (-CH2CH(CH3)-), etc.

[0075] As used herein, the term "alkenyl" refers to a monovalent group derived from a hydrocarbon portion comprising at least two carbon atoms and at least one carbon-carbon double bond. A double bond may or may not be a point of attachment to another group. Alkenyl groups (e.g., C2-C8-alkenyl) include, but are not limited to, for example, vinyl, propenyl, prop-1-ene-2-yl, butenyl, 1-methyl-2-butene-1-yl, heptenyl, octenyl, etc.

[0076] As used herein, the term "alkynyl" refers to a monovalent group derived from a hydrocarbon portion comprising at least two carbon atoms and at least one carbon-carbon triple bond. A triple bond may or may not be a point of attachment to another group. Alkynyl groups (e.g., C2-C8-alkynyl) include, but are not limited to, for example, ethynyl, propynyl, prop-1-yn-2-yl, butynyl, 1-methyl-2-butyn-1-yl, heptynyl, octynyl, etc.

[0077] As used herein, the term "alkoxy" refers to the group -O-alkyl, wherein alkyl is as defined herein. Alkoxy includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, and the like.

[0078] As used herein, the term "cycloalkyl" means a partially or fully saturated non-aromatic carbocyclic ring system with 1, 2 or 3 rings, wherein such rings can be fused. The term "fused" means that the second ring exists (i.e., is connected or formed) by having (i.e., sharing) two adjacent atoms with the first ring. Cycloalkyl also includes a bicyclic structure, which can be bridged or spirocyclic in nature, wherein each individual ring in the bicyclic changes from 3-8 atoms. The term "cycloalkyl" includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl, spiro [3.3] heptyl and bicyclo [1.1.1] pentyl.

[0079] As used herein, the term "heterocyclyl" means a non-aromatic carbocyclic ring system containing 1, 2, 3 or 4 heteroatoms (independently selected from N, O and S) and having 1, 2 or 3 rings, wherein such rings may be fused, wherein the fusion is defined above. Heterocyclyl also includes bicyclic structures, which may be bridged or spirocyclic in nature, wherein each individual ring within the bicyclic ring varies from 3-8 atoms and contains 0, 1 or 2 N, O or S atoms. The term "heterocyclyl" includes cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams), and also specifically includes, but is not limited to, epoxidyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl, dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinyl, 1,3-thiazinyl, and the like. For example, the term "heterocyclyl" can include a 4- to 10-membered heterocyclyl, a 4- to 7-membered heterocyclyl, a 5- to 10-membered heterocyclyl, a 6- to 10-membered heterocyclyl, a 4- to 6-membered heterocyclyl, a 4-membered heterocyclyl, a 5-membered heterocyclyl, a 6-membered heterocyclyl, a 7-membered heterocyclyl, an 8-membered heterocyclyl, a 9-membered heterocyclyl, or a 10-membered heterocyclyl.

[0080] As used herein, the term "aromatic" refers to a carbocyclic or heterocyclic ring having one or more polyunsaturated rings and having aromatic character, ie, having (4n+2) delocalized π (pi) electrons, where n is an integer.

[0081] As used herein, the term "aryl" means an aromatic carbocyclic ring system comprising 1, 2 or 3 rings, wherein such rings may be fused, wherein fusion is defined above. If the rings are fused, one of the rings must be fully unsaturated, and one or more of the fused rings may be fully saturated, partially unsaturated or fully unsaturated. The term "aryl" includes, but is not limited to, phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl. For example, the term "aryl" may include C6-C 10 aryl, C6-C8 aryl or C6 aryl (ie, phenyl).

[0082] As used herein, the term "heteroaryl" means an aromatic carbocyclic ring system comprising 1, 2, 3 or 4 heteroatoms (independently selected from N, O and S) and having 1, 2 or 3 rings, wherein such rings may be fused, wherein the fused is defined above. The term "heteroaryl" includes, but is not limited to, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc. For example, the term "heteroaryl" can include 5- to 10-membered heteroaryl, 5- to 8-membered heteroaryl, 5- to 6-membered heteroaryl, 6- to 10-membered heteroaryl, 6- to 8-membered heteroaryl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl, or 10-membered heteroaryl.

[0083] It should be understood that if an aryl, heteroaryl, cycloalkyl or heterocyclyl moiety can be bonded or otherwise attached to a specified moiety through different ring atoms (i.e., is shown or described without indicating a specific point of attachment), all possible points are contemplated, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term "pyridyl" means 2-, 3-, or 4-pyridyl, the term "thienyl" means 2- or 3-thienyl, and so on.

[0084] As used herein, the term "substituted" means that an atom or group of atoms has replaced a hydrogen as a substituent attached to another group.

[0085] Compounds of the present invention

[0086] Therefore, in a first aspect, the present invention provides a compound represented by Formula IA or a pharmaceutically acceptable salt thereof:

[0087]

[0088] in:

[0089] Ring A is fused to ring B;

[0090] Ring A is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0091] Ring B is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0092] X is N or CH;

[0093] Y is S(=O)2, C(=O) or S(=O)(=NR e );

[0094] R e Selected from the group consisting of H, C1-C3 alkyl or C3-C5 cycloalkyl;

[0095] E is selected from the group consisting of: NR a R b 、C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl, and C1-C3 alkylene-(5- to 7-membered heteroaryl), wherein the C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl) is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution;

[0096] R a and R bEach independently selected from the group consisting of H, C1-C3 alkyl, C3-C5 cycloalkyl and 4- to 7-membered heterocyclyl; wherein the C1-C3 alkyl, C3-C5 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxy;

[0097] Or, alternatively, R a and R b Together with the N atom to which they are attached, they form a 4- to 7-membered heterocyclyl or a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , C1-C3 alkyl, C1-C3 alkoxy or C1-C3 alkyl substituted by 1-3 halogens;

[0098] R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 Aryl), C(=O)-(CR c R d ) n -(5- to 10-membered heteroaryl), C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclic group), (CR c R d ) n -(C6-C 10 Aryl) and (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10Aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0099] R c and R d Each is independently H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogens or deuterium;

[0100] n is 0, 1, or 2;

[0101] Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium;

[0102] Or, alternatively, R3 and R6 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0103] Or, alternatively, R4 and R5 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0104] m is 0 or 1;

[0105] p is 0, 1, 2, 3 or 4; and

[0106] Each R9 is independently selected from the group consisting of deuterium, halogen, hydroxyl and cyano.

[0107] In one embodiment, provided herein is a compound of Formula IA having the structure of Formula I or a pharmaceutically acceptable salt thereof:

[0108]

[0109] in:

[0110] Ring A is fused to ring B;

[0111] Ring A is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0112] Ring B is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0113] X is N or CH;

[0114] Y is S(=O)2, C(=O) or S(=O)(=NR e );

[0115] R e Selected from the group consisting of H, C1-C3 alkyl or C3-C5 cycloalkyl;

[0116] E is selected from the group consisting of: NR a R b 、C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl, and C1-C3 alkylene-(5- to 7-membered heteroaryl), wherein the C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl) is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution;

[0117] R a and R bEach independently selected from the group consisting of H, C1-C3 alkyl, C3-C5 cycloalkyl and 4- to 7-membered heterocyclyl; wherein the C1-C3 alkyl, C3-C5 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxy;

[0118] Or, alternatively, R a and R b Together with the N atom to which they are attached, they form a 4- to 7-membered heterocyclyl or a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , C1-C3 alkyl, C1-C3 alkoxy or C1-C3 alkyl substituted by 1-3 halogens;

[0119] R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 Aryl), C(=O)-(CR c R d ) n -(5- to 10-membered heteroaryl), C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclic group), (CR c R d ) n -(C6-C 10 Aryl) and (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10Aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium;

[0120] R c and R d Each is independently H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogens or deuterium;

[0121] n is 0, 1, or 2;

[0122] Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium;

[0123] Or, alternatively, R3 and R6 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0124] Or, alternatively, R4 and R5 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens;

[0125] m is 0 or 1;

[0126] p is 0, 1, 2, 3 or 4; and

[0127] Each R9 is independently selected from the group consisting of deuterium, halogen, hydroxyl and cyano.

[0128] In one embodiment of formula (I), Ring A is selected from the group consisting of 4- to 7-membered heterocyclyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclic group, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0129] In another embodiment of formula (I), Ring A is selected from the group consisting of: C3-C8 cycloalkyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0130] In another embodiment of formula (I), Ring A is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0131] In another embodiment of formula (I), Ring A is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and C6-C 10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0132] In another embodiment of formula (I), Ring A is selected from the group consisting of: C6-C 10 Aryl and 5- to 7-membered heteroaryl, wherein the C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0133] In another embodiment of formula (I), Ring A is selected from the group consisting of: C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0134] In another embodiment of formula (I), Ring A is selected from the group consisting of C3-C8 cycloalkyl and C6-C 10 Aryl, wherein the C3-C8 cycloalkyl or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0135] In another embodiment of formula (I), Ring A is selected from the group consisting of 4- to 7-membered heterocyclyl and C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group or C6-C 10Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0136] In another embodiment of formula (I), Ring A is selected from the group consisting of a 4- to 7-membered heterocyclyl and a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0137] In another embodiment of formula (I), Ring A is a C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0138] In another embodiment of formula (I), Ring A is a 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0139] In another embodiment of Formula (I), Ring A is C6-C 10 Aryl, wherein the C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0140] In another embodiment of formula (I), Ring A is a 5- to 7-membered heteroaryl, wherein the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0141] In another embodiment of formula (I), Ring B is selected from the group consisting of 4- to 7-membered heterocyclyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclic group, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0142] In another embodiment of formula (I), Ring B is selected from the group consisting of: C3-C8 cycloalkyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0143] In another embodiment of formula (I), Ring B is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0144] In another embodiment of formula (I), Ring B is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and C6-C 10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0145] In another embodiment of formula (I), Ring B is selected from the group consisting of: C6-C 10 Aryl and 5- to 7-membered heteroaryl, wherein the C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0146] In another embodiment of formula (I), Ring B is selected from the group consisting of C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0147] In another embodiment of formula (I), Ring B is selected from the group consisting of C3-C8 cycloalkyl and C6-C 10 Aryl, wherein the C3-C8 cycloalkyl or C6-C 10Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0148] In another embodiment of formula (I), Ring B is selected from the group consisting of 4- to 7-membered heterocyclyl and C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0149] In another embodiment of formula (I), Ring B is selected from the group consisting of a 4- to 7-membered heterocyclyl and a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0150] In another embodiment of formula (I), Ring B is a C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0151] In another embodiment of formula (I), Ring B is a 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0152] In another embodiment of Formula (I), Ring B is C6-C 10 Aryl, wherein the C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0153] In another embodiment of formula (I), Ring B is a 5- to 7-membered heteroaryl, wherein the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0154] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of: 4- to 7-membered heterocyclyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclic group, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0155] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of: C3-C8 cycloalkyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0156] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0157] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and C6-C 10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0158] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of: C6-C 10 Aryl and 5- to 7-membered heteroaryl, wherein the C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0159] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of: C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0160] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of: C3-C8 cycloalkyl and C6-C 10 Aryl, wherein the C3-C8 cycloalkyl or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0161] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of a 4- to 7-membered heterocyclyl and a C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0162] In another embodiment of formula (I), Ring A and Ring B are each independently selected from the group consisting of a 4- to 7-membered heterocyclyl and a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0163] In another embodiment of Formula (I), Ring A is a 5- to 7-membered heteroaryl and Ring B is C6-C 10 aryl, wherein the 5- to 7-membered heteroaryl and C6-C 10 Each aryl group is independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0164] In another embodiment of Formula (I), Ring A is a 5- to 7-membered heteroaryl and Ring B is a 5- to 7-membered heteroaryl, wherein each 5- to 7-membered heteroaryl is independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0165] In another embodiment of formula (I), Ring A is a 4- to 7-membered heterocyclyl and Ring B is C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group and C6-C 10 Each aryl group is independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0166] In another embodiment of Formula (I), Ring A is a 4- to 7-membered heterocyclyl and Ring B is a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl and the 5- to 7-membered heteroaryl are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0167] In another embodiment of Formula (I), Ring A is C3-C8 cycloalkyl and Ring B is C6-C 10 Aryl, wherein the C3-C8 cycloalkyl and C6-C 10 Each aryl group is independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0168] In another embodiment of Formula (I), Ring A is C3-C8 cycloalkyl and Ring B is 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl and 5- to 7-membered heteroaryl are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0169] In another embodiment of formula (I), is selected from the group consisting of benzimidazolyl, 1H-pyrazolo[3,4-c]pyridinyl, imidazo[1,5-a]pyridinyl, indolyl, isoindolyl, indolyl, indazolyl, isoindazolyl, benzothiazolyl, purinyl, benzofuranyl, benzisoxazolyl, benzisothiazolyl, isobenzofuranyl, benzothiofuranyl, indoleninyl, pyrano[3,4-b]-pyrrolyl, indoxazinyl, benzoxazolyl, anthranilyl and indolizinyl, wherein the benzimidazolyl Oxylidene, 1H-pyrazolo[3,4-c]pyridinyl, imidazo[1,5-a]pyridinyl, indolyl, isoindolyl, indolyl, indazolyl, isoindazolyl, benzothiazolyl, purinyl, benzofuranyl, benzisoxazolyl, benzisothiazolyl, isobenzofuranyl, benzothiofuranyl, indolenolyl, pyrano[3,4-b]-pyrrolyl, indoloxazinyl, benzoxazolyl, o-aminobenzoyl and indolizinyl are unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0170] In another embodiment of formula (I), It is a benzimidazolyl group, wherein the benzimidazolyl group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0171] In another embodiment of formula (I), is 1H-pyrazolo[3,4-c]pyridinyl, wherein the 1H-pyrazolo[3,4-c]pyridinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0172] In another embodiment of formula (I), It is imidazo[1,5-a]pyridinyl, wherein the imidazo[1,5-a]pyridinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0173] In another embodiment of formula (I), is indolyl, wherein the indolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0174] In another embodiment of formula (I), is isoindole, wherein the isoindole is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0175] In another embodiment of formula (I), It is indolinyl, wherein the indolinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0176] In another embodiment of formula (I), is indazolyl, wherein the indazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0177] In another embodiment of formula (I), is isoindazolyl, wherein the isoindazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0178] In another embodiment of formula (I), is benzothiazolyl, wherein the benzothiazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0179] In another embodiment of formula (I), is a purinyl group, wherein the purinyl group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0180] In another embodiment of formula (I), is benzofuranyl, wherein the benzofuranyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0181] In another embodiment of formula (I), is benzisoxazolyl, wherein the benzisoxazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0182] In another embodiment of formula (I), is a benzisothiazolyl group, wherein the benzisothiazolyl group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0183] In another embodiment of formula (I), isobenzofuranyl, wherein the isobenzofuranyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0184] In another embodiment of formula (I), is benzothiofuranyl, wherein the benzothiofuranyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0185] In another embodiment of formula (I), is an indolenine group, wherein the indolenine group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0186] In another embodiment of formula (I), It is pyrano[3,4-b]-pyrrolyl, wherein the pyrano[3,4-b]-pyrrolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0187] In another embodiment of formula (I), is indoloxazinyl, wherein the indoloxazinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0188] In another embodiment of formula (I), is benzoxazolyl, wherein the benzoxazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0189] In another embodiment of formula (I), is anthranilyl, wherein the anthranilyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0190] In another embodiment of formula (I), is indolizinyl, wherein the indolizinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0191] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0192] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0193] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0194] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0195] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0196] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0197] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0198] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1 substituent selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0199] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0200] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0201] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0202] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0203] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0204] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0205] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0206] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0207] In another embodiment of formula (I), yes It is unsubstituted or substituted by 1 to 3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0208] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0209] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0210] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0211] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1 substituent selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1 to 3 halogen or deuterium atoms.

[0212] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0213] In another embodiment of formula (I), yes It is unsubstituted or further substituted by 1-2 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

[0214] In another embodiment of formula (I), p is 0. In another embodiment of formula (I), p is 1. In another embodiment of formula (I), p is 2. In another embodiment of formula (I), p is 3. In another embodiment of formula (I), p is 4. In another embodiment of formula (I), p is 0, 1 or 2. In another embodiment of formula (I), p is 0 or 1.

[0215] In another embodiment of formula (I), p is 1 and R9 is deuterium. In another embodiment of formula (I), p is 1 and R9 is halogen. In another embodiment of formula (I), p is 1 and R9 is fluorine. In another embodiment of formula (I), p is 1 and R9 is hydroxyl. In another embodiment of formula (I), p is 1 and R9 is cyano. In another embodiment of formula (I), p is 2 and each R9 is hydroxyl. In another embodiment of formula (I), p is 2 and each R9 is halogen. In another embodiment of formula (I), p is 2 and each R9 is fluorine.

[0216] In another embodiment of Formula (I), E is NR a R b In another embodiment of formula (I), E is C1-C3 alkylene-NR a R b . In another embodiment of formula (I), E is an unsubstituted C1-C3 alkyl, an unsubstituted C2-C4 alkenyl or an unsubstituted C2-C4 alkynyl. In another embodiment of formula (I), E is a C1-C3 alkyl, a C2-C4 alkenyl or a C2-C4 alkynyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxy. In another embodiment of formula (I), E is an unsubstituted C1-C3 alkyl. In another embodiment of formula (I), E is an unsubstituted C1-C3 alkyl. c R d In another embodiment of formula (I), E is an unsubstituted C3-C8 cycloalkyl. In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d In another embodiment of formula (I), E is unsubstituted C1-C3 alkylene-(C3-C8 cycloalkyl). In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R dIn another embodiment of formula (I), E is an unsubstituted 4- to 10-membered heterocyclyl. In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d In another embodiment of formula (I), E is an unsubstituted C1-C3 alkylene-(4- to 10-membered heterocyclyl). In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(4- to 10-membered heterocyclyl). In another embodiment of formula (I), E is an unsubstituted C6-C 10 In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C6-C substituted by C1-C3 alkyl or C1-C3 alkoxy 10 In another embodiment of formula (I), E is an unsubstituted C1-C3 alkylene-(C6-C 10 In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(C6-C 10 In another embodiment of formula (I), E is an unsubstituted 5- to 7-membered heteroaryl. In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d In another embodiment of formula (I), E is an unsubstituted C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(5- to 7-membered heteroaryl).

[0217] In another embodiment of formula (I), E is C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl), wherein the C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl) is unsubstituted or replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution.

[0218] In another embodiment of formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl), wherein the C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl) is unsubstituted or replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution.

[0219] In another embodiment of formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl), wherein the C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl) is unsubstituted or substituted with one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution.

[0220] In another embodiment of formula (I), E is methyl. In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d In another embodiment of formula (I), E is CF3. In another embodiment of formula (I), E is CHF2. In another embodiment of formula (I), E is CH2F. In another embodiment of formula (I), E is NH(CH3). In another embodiment of formula (I), E is N(CH3)2.

[0221] In another embodiment of Formula (I), E is C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 In another embodiment of formula (I), E is an unsubstituted C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl).

[0222] In another embodiment of formula (I), E is a 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of formula (I), E is an unsubstituted 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of formula (I), E is substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl).

[0223] In another embodiment of formula (I), Y is S(=O)2. In another embodiment of formula (I), Y is C(=O). In another embodiment of formula (I), Y is S(=O)(=NR e ).

[0224] In another embodiment of formula (I), X is N. In another embodiment of formula (I), X is CH.

[0225] In another embodiment of formula (I), R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c Rd ) n -(C6-C 10 aryl) and C(═O)-(CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0226] In another embodiment of formula (I), R1 is selected from the group consisting of C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy and C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, wherein the C1-C4 alkyl, C1-C4 alkoxy or C3-C8 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0227] In another embodiment of formula (I), R1 is selected from the group consisting of: C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 aryl) and C(═O)-(CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0228] In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkyl, wherein the C1-C4 alkyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0229] In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkoxy, wherein the C1-C4 alkoxy is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0230] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0231] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0232] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0233] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0234] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5- to 7-membered heterocyclyl), wherein the 5- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0235] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5- to 6-membered heterocyclyl), wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0236] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5-membered heterocyclyl), wherein the 5-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0237] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heterocyclyl), wherein the 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0238] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6 aryl), wherein the C6 aryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0239] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C8 aryl), wherein the C8 aryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0240] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C 10 aryl), wherein the C 10Aryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0241] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0242] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0243] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0244] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(7-membered heteroaryl), wherein the 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0245] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl or C(=O)-O-(CR c R d ) n-(4- to 7-membered heterocyclyl), wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C5 cycloalkyl, wherein the C3-C5 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5- to 6-membered heterocyclyl), wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), wherein the 5-membered heterocyclyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), wherein the 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0246] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0247] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium, and further wherein n is 0.

[0248] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c Rd ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 1. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0249] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 The aryl group is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0250] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 The aryl group is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

[0251] In another embodiment of Formula (I), R1 is (CR cR d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted, and further wherein n is 1. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 The aryl group is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0252] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0253] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

[0254] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 1. In another embodiment of Formula (I), R1 is (CR c R d ) n-(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0255] In another embodiment of Formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0256] In another embodiment of Formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

[0257] In another embodiment of Formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n-(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted, and further wherein n is 1. In another embodiment of formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0258] In another embodiment of Formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

[0259] In another embodiment of Formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

[0260] In another embodiment of Formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is unsubstituted, and further wherein n is 1. In another embodiment of formula (I), R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0261] In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of formula (I), R1 is pyridazinyl. In another embodiment of formula (I), R1 is 3-pyridazinyl.

[0262] In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

[0263] In another embodiment of Formula (I), R1 is (CR c R d ) n-(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted, and further wherein n is 1. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0264] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted. In another embodiment of formula (I), R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

[0265] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted, and further wherein n is 0. In another embodiment of formula (I), R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

[0266] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted, and further wherein n is 1. In another embodiment of formula (I), R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

[0267] In another embodiment of formula (I), each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogens or deuterium. In another embodiment of formula (I), each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), each of R2, R3, R4, R5, R6, R7 and R8 is independently H or halogen. In another embodiment of formula (I), each of R2, R3, R4, R5, R6, R7 and R8 is independently H or fluorine. In another embodiment of formula (I), each of R2, R3, R4, R5, R6, R7 and R8 is independently H or C1-C3 alkyl. In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7 and R8 is H.

[0268] In another embodiment of formula (I), R3 and R6 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted with one or more halogens. In another embodiment of formula (I), R3 and R6 together form an unsubstituted C2 alkylene or a C2 alkylene substituted with one or more halogens. In another embodiment of formula (I), R3 and R6 together form an azabicyclo[3.2.1]octyl bridged bicyclic heterocyclyl.

[0269] In another embodiment of formula (I), R4 and R5 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted with one or more halogens. In another embodiment of formula (I), R4 and R5 together form an unsubstituted C2 alkylene or a C2 alkylene substituted with one or more halogens. In another embodiment of formula (I), R4 and R5 together form an azabicyclo[3.2.1]octyl bridged bicyclic heterocyclyl.

[0270] In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0271] In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkoxy and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkoxy and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkoxy and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-C1-C4 alkoxy and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0272] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0273] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n-C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0274] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0275] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0276] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0277] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0278] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0279] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0280] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0281] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0282] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0283] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0284] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0285] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(═O)-(CRc R d ) n -(C6-C 10 In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6-C 10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0286] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6-C 10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6-C 10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0287] In another embodiment of formula (I), R1 is C(═O)-(CR c R d )n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0288] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0289] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n-(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0290] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0291] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n-(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0292] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0293] In another embodiment of formula (I), R1 is C(═O)-(CR c R d )n -(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0294] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0295] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n-(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0296] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0297] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0298] In another embodiment of formula (I), R1 is C(═O)-(CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0299] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n-C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0300] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0301] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n-C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0302] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0303] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0304] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0305] In another embodiment of formula (I), R1 is C(=O)-O-(CR cR d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0306] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0307] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d )n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0308] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0309] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0310] In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0311] In another embodiment of Formula (I), R1 is (CR c R d ) n-(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0312] In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CR c R d ) n -(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0313] In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c Rd ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0314] In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0315] In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 1 or 2 and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0316] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6-C 10 In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 In another embodiment of formula (I), R1 is (CR c R d ) n -(C6-C 10 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0317] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of formula (I), R1 is (CR c R d ) n-(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6 aryl) and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluoro.

[0318] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0319] In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H. In another embodiment of Formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R1 is (CR c Rd ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or halogen. In another embodiment of formula (I), R1 is (CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H or fluorine.

[0320] Each of the embodiments described herein with respect to compounds of Formula I also applies to compounds of Formula IA.

[0321] Certain embodiments of compounds of Formula IA or I, or pharmaceutically acceptable salts thereof, are shown below in Table 1. Compounds of Formula IA or I, or pharmaceutically acceptable salts thereof, and compounds of Table 1, or pharmaceutically acceptable salts thereof, are sometimes collectively or individually referred to herein as "compounds of the invention" or "compounds provided herein."

[0322] Table 1

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339] The disclosed compounds have one or more stereocenters, and each stereocenter can independently exist in the R or S configuration. In one embodiment, the compounds described herein exist in optically active or racemic forms. It should be understood that the compounds described herein include racemic, optically active, regioisomeric and stereoisomeric forms or combinations thereof having the therapeutically useful properties described herein.

[0340] The preparation of optically active forms is achieved in any suitable manner, including, for example, but not limited to, by resolving racemic forms with recrystallization techniques, synthesizing from optically active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. In one embodiment, a mixture of two or more isomers is used as the disclosed compounds described herein. In another embodiment, pure isomers are used as the disclosed compounds described herein. In another embodiment, the compounds described herein contain one or more chiral centers. These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis, or separation of enantiomers or mixtures of diastereomers. The resolution of compounds and isomers thereof is achieved by any means, including, for example, but not limited to chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.

[0341] In one embodiment, the disclosed compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein.

[0342] The compounds described herein also include isotopically labeled compounds in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of suitable isotopes for inclusion in the compounds described herein include, but are not limited to 2 H. 3 H. 11 C. 13 C. 14 C. 36 Cl, 18 F. 123 I. 125 I. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P and 35S. In one embodiment, isotopically labeled compounds are useful in drug or substrate tissue distribution studies. In another embodiment, substitution with heavier isotopes such as deuterium provides greater metabolic stability (e.g., increasing in vivo half-life or reducing dosage requirements). In another embodiment, the compounds described herein include 2 H (i.e. deuterium) isotope.

[0343] In yet another embodiment, a positron emitting isotope such as 11 C. 18 F. 15 O and 13 N) substitution can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds are prepared by any suitable method or process by using an appropriate isotopically labeled reagent in place of the unlabeled reagent otherwise employed.

[0344] Specific compounds described herein, as well as other compounds encompassed by one or more of the formulae described herein with various substituents, are synthesized using the techniques and materials described herein and as described in, for example, Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4 thEd., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosures). The general methods for preparing the compounds described herein are modified by using appropriate reagents and conditions to introduce the various moieties present in the formulas provided herein.

[0345] The compounds described herein are synthesized using any suitable procedures starting from compounds available from commercial sources or prepared using the procedures described herein.

[0346] Treatment

[0347] The compounds of the present invention can be used in a method for treating a disease or condition in a subject, the method comprising administering a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention to the subject. In one embodiment of the methods described herein, the subject is a human. In one aspect, the compounds provided herein can be used to treat a disease or condition by acting as an agonist of the orexin-2 receptor.

[0348] The compounds of the present invention are useful for treating a disease or condition selected from the group consisting of narcolepsy, cataplexy or hypersomnia in a subject in need thereof.

[0349] In one embodiment, the compounds of the invention are useful for treating narcolepsy in a subject. In one embodiment, the compounds of the invention are useful for treating cataplexy in a subject. In one embodiment, the compounds of the invention are useful for treating hypersomnia in a subject.

[0350] Orexin-2 receptors are important in a wide range of biological functions. This suggests that orexin-2 receptors play a role in a variety of disease processes in humans or other species. The compounds of the present invention can be used to treat, prevent or ameliorate one or more of the following symptoms or risks of various neurological and psychiatric diseases associated with alterations in sleep / wake function. That is, narcolepsy, narcolepsy with cataplexy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnia syndrome characterized by hypersomnia (e.g., in subjects with Kleine-Levin syndrome, major depression with hypersomnia, Lewy body dementia, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Mobius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, multiple system atrophy, acute disseminated encephalomyelitis, Guillain-Barré syndrome, Rasmussen's encephalitis, Wernicke's encephalitis, limbic encephalitis, or Hashimoto's encephalopathy), coma, loss of consciousness, obesity (e.g.,Malignant mastocytosis, exogenous obesity, hyperinsulinar obesity, hyperplasmic obesity, hypopituitarism, hypoplasmosis, hypothyroidism, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, dietary obesity, hypogonadism, systemic mastocytosis, simple obesity or central obesity), insulin resistance syndrome, Alzheimer's disease, consciousness disorders such as coma, side effects and complications due to anesthesia, sleep disorders, excessive daytime sleepiness, sleep problems, insomnia, intermittent sleep, nocturnal myoclonus, REM sleep interruption, jet lag, jet lag syndrome, sleep disorders in shift workers, sleep disorders, night terrors, depression, major depression, sleepwalking, enuresis, sleep disorders, Alzheimer's sunset syndrome (Alzheimer's dusk,sundowning), circadian rhythm-related disorders, fibromyalgia, disorders caused by decreased sleep quality, overeating, compulsive eating disorders, obesity-related disorders, hypertension, diabetes, elevated plasma insulin concentrations and insulin resistance, hyperlipidemia, hyperlipidemia, endometrial cancer, breast cancer, prostate cancer, colorectal cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heartbeat, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, polycystic ovary disease, craniopharyngioma, Prader-Willi syndrome, Froelich's syndrome syndrome), growth hormone deficiency, normal mutant short stature, Turner's syndrome, children with acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormalities, decreased fertility, infertility, male hypogonadism, sexual and reproductive dysfunction such as hirsutism in women, fetal defects associated with maternal obesity, gastrointestinal motility disorders such as obesity-related gastroesophageal reflux, obesity hypoventilation syndrome (Pickwick syndrome), respiratory diseases such as dyspnea, inflammation such as systemic inflammation of the vascular system, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease, gout, kidney cancer, risk of secondary consequences of obesity such as reduced risk of left ventricular hypertrophy, migraine pain, headache, neuropathic pain, Parkinson's disease, psychosis, autoimmune encephalitis, cancer-related fatigue (such as,excessive daytime sleepiness or fatigue related to cancer and / or chemotherapy), cancer-related nausea and vomiting, corticobasal degeneration, Huntington's disease, neuromyelitis optica, nociception, progressive supranuclear palsy, schizophrenia, systemic lupus erythematosus, traumatic brain injury, facial flushing, night sweats, reproductive / urinary system disorders, disorders related to sexual function or fertility, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymia, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attacks, panic disorder, post-traumatic stress disorder (PTSD), separation anxiety disorder, social phobia, anxiety disorders, acute neurological and psychiatric Disorders such as brain defect after heart bypass surgery and transplantation, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neurological damage, Huntington's disease, amyotrophic lateral sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorders related to muscle spasticity, delirium, amnestic disorders, age-related cognitive decline, schizoaffective disorder, delusional disorder, drug addiction, movement disorders, chronic fatigue syndrome, fatigue, drug-induced parkinsonism, Tourette's syndrome, chorea, myoclonus, tics, restless legs syndrome, dystonia, movement disorders, attention deficit hyperactivity disorder (ADHD), behavioral disorders, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, neurological damage, retinopathy, macular degeneration, vomiting, brain edema, pain, bone pain, joint pain, toothache, cataplexy and traumatic brain injury (TBI). ,

[0351] In particular, the compound of the present invention can be used as a therapeutic or preventive drug for narcolepsy, idiopathic hypersomnia, somnolence, sleep apnea syndrome, narcolepsy syndrome, hypersomnia syndrome characterized by somnolence (for example, in Parkinson's disease, Guillain-Barré syndrome or Kleine-Levin syndrome), Alzheimer's disease, obesity, insulin resistance syndrome, heart failure, diseases associated with bone loss, sepsis, consciousness disorders such as coma, side effects and complications due to anesthesia, etc., or an anesthetic antagonist.

[0352] In one embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a preventive or therapeutic agent for narcolepsy.

[0353] In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for narcolepsy type 1. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for narcolepsy type 2. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for narcolepsy and excessive daytime sleepiness. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for narcolepsy, cataplexy, and excessive daytime sleepiness. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for narcolepsy and cataplexy. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for excessive daytime sleepiness. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for idiopathic hypersomnia. In another embodiment, the compounds of the present invention can be used as a preventive or therapeutic agent for obstructive sleep apnea.

[0354] In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as preventive or therapeutic agents for somnolence in Parkinson's disease.

[0355] In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as preventive or therapeutic agents for drowsiness. In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as preventive or therapeutic agents for excessive daytime sleepiness associated with Parkinson's disease.

[0356] In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as preventive or therapeutic agents for excessive daytime sleepiness or fatigue associated with cancer and / or chemotherapy.

[0357] In another embodiment, the present invention provides a method of treating narcolepsy in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0358] In another embodiment, the present invention provides a method of treating narcolepsy type 1 in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0359] In another embodiment, the present invention provides a method of treating narcolepsy type 2 in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0360] In another embodiment, the present invention provides a method of treating narcolepsy and excessive daytime sleepiness in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0361] In another embodiment, the present invention provides a method of treating narcolepsy, cataplexy, and excessive daytime sleepiness in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0362] In another embodiment, the present invention provides a method of treating narcolepsy and cataplexy in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0363] In another embodiment, the present invention provides a method of treating excessive daytime sleepiness in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0364] In another embodiment, the present invention provides a method of treating idiopathic hypersomnia in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0365] In another embodiment, the present invention provides a method of treating excessive daytime sleepiness and essential hypersomnia in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0366] In another embodiment, the present invention provides a method of treating obstructive sleep apnea in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0367] In another embodiment, the present invention provides a method of treating excessive daytime sleepiness and obstructive sleep apnea in a subject in need thereof, comprising administering to the subject a compound of Formula IA or I or a pharmaceutically acceptable salt thereof.

[0368] In any of the methods described herein, a compound of Formula I is administered to a subject.

[0369] Each embodiment described herein with respect to the use of compounds of Formula I also applies to compounds of Formula IA.

[0370] In any of the compositions or methods described herein, the compound of Formula IA or I, or a pharmaceutically acceptable salt thereof, is present and / or administered in a therapeutically effective amount.

[0371] Administration / dosage / formulation

[0372] In another aspect, provided herein are pharmaceutical compositions comprising at least one compound of the present invention and a pharmaceutically acceptable carrier.

[0373] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0374] In particular, the selected dosage level will depend upon a variety of factors, including the activity of the specific compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient to be treated, and like factors well known in the medical arts.

[0375] A physician, such as a doctor or veterinarian, having ordinary skills in the art can easily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian can initially administer the pharmaceutical composition, dosing the disclosed compound at a level below that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.

[0376] In certain embodiments, it is particularly advantageous to formulate the compounds in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as unitary dosages for the patient to be treated; each unit containing a predetermined amount of a disclosed compound calculated to produce the desired therapeutic effect in combination with the required drug carrier. The dosage unit form of the present invention is dictated by and directly dependent on (a) the unique characteristics of the disclosed compounds and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such disclosed compounds for use in treating narcolepsy or cataplexy in patients.

[0377] In one embodiment, the compounds of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions of the invention include a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.

[0378] In some embodiments, the dosage of the disclosed compound is from about 1 mg to about 1,000 mg. In some embodiments, the dosage of the disclosed compound used in the compositions described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 20 mg, or less than about 10 mg. For example, the dosage is about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240, 260 mg, 280 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or about 600 mg.

[0379] Any one of the routes of administration in the composition of the present invention includes oral, nasal, rectal, intravaginal, parenteral, oral, sublingual or local. Compounds used for the present invention can be formulated for administration by any suitable route, such as for oral or parenteral, for example, percutaneous, through mucosal (for example, sublingual, tongue, (through) oral cavity, (through) urethra, vagina (for example, vaginal and around vagina), nose (in) and (through) rectum), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, suction and topical administration. In one embodiment, preferred route of administration is oral.

[0380] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, lozenges, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, sera, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powders or aerosolized formulations for inhalation, compositions and formulations for intravesical administration, etc. It should be understood that the formulations and compositions that will be useful in the present invention are not limited to the specific formulations and compositions described herein.

[0381] For oral use, tablets, dragees, liquids, drops, suppositories or capsules, caplets and gelatin capsules are particularly suitable. Compositions intended for oral use can be prepared according to any method known in the art, and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutical excipients suitable for making tablets. Such excipients include, for example, inert diluents such as lactose; granulating and disintegrants such as corn starch; binders such as starch; and lubricants such as magnesium stearate. Tablets may not be coated, or they may be coated by known techniques to improve quality or delay the release of the active ingredient. Preparations for oral use may also be present in hard gelatin capsules, in which the active ingredient is mixed with an inert diluent.

[0382] For parenteral administration, the disclosed compounds can be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration by bolus dose or continuous infusion. Suspensions, solutions or emulsions in oily or aqueous vehicles can be used, optionally containing other formulating agents, such as suspending agents, stabilizers or dispersing agents.

[0383] Those skilled in the art will recognize or be able to determine many equivalents of the specific procedures, embodiments, claims and embodiments described herein using only routine experiments. Such equivalents are considered to be within the scope of the present invention and are covered by the claims appended hereto. For example, it should be understood that modifications of reaction conditions including but not limited to reaction time, reaction size / volume and experimental reagents such as solvents, catalysts, pressures, atmospheric conditions (e.g., nitrogen atmosphere) and reducing / oxidizing agents using art-recognized alternatives and using only routine experiments are within the scope of the present application.

[0384] It should be understood that no matter where values ​​and ranges are provided herein, all values ​​and ranges encompassed by these values ​​and ranges are intended to be encompassed within the scope of the present invention. In addition, this application also contemplates all values ​​falling within these ranges and the upper or lower limit of the value range.

[0385] The following examples further illustrate aspects of the present invention. However, they in no way limit the teachings or disclosure of the present invention set forth herein.

[0386] Example

[0387] The present invention is further illustrated by the following examples, which should not be construed as further limiting. Unless otherwise indicated, the practice of the present invention will employ conventional techniques of organic synthesis, cell biology, cell culture, molecular biology, transgenic biology, microbiology and immunology, which are within the skill of the art.

[0388] General Procedures

[0389] Example 1: Synthesis Procedure

[0390] The synthetic procedures for preparing the compounds of the present invention are readily available to those of ordinary skill in the art. Unless otherwise indicated, the starting materials are generally obtained from commercial sources. The synthetic procedures for other related compounds can be found, for example, in U.S. Application No. 17 / 556,295 filed on December 20, 2021 and PCT Application No. PCT / US21 / 64484 filed on December 21, 2021; both are expressly incorporated herein by reference.

[0391] The following abbreviations may be used in the following synthetic examples:

[0392] DCM = dichloromethane

[0393] MeOH = methanol

[0394] EtOH = ethanol

[0395] DIPEA or DIEA = N,N-diisopropylethylamine

[0396] ACN or MeCN = acetonitrile

[0397] PE = Petroleum Ether

[0398] EtOAc = Ethyl acetate

[0399] TFA = trifluoroacetic acid

[0400] DMSO = dimethyl sulfoxide

[0401] i-PrOH=isopropyl alcohol

[0402] EA = Ethyl acetate

[0403] Pd / C = Palladium on Carbon

[0404] Boc=tert-butyloxycarbonyl

[0405] Ms = Methanesulfonyl

[0406] Bn=Benzyl

[0407] Bz = benzoyl

[0408] P(OPh)3=triphenyl phosphite

[0409] Et=ethyl

[0410] h = hours

[0411] min = minutes

[0412] PdCl2(dppf)=[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)

[0413] DMAP = 4-(dimethylamino)pyridine

[0414] KOAc = Potassium acetate

[0415] Et3N or TEA = triethylamine

[0416] TMS-Cl = trimethylsilyl chloride

[0417] LiNEt2=Lithium diethylamide

[0418] SFC = Supercritical Fluid Chromatography

[0419] PEPPSI = Pyridine Enhanced Precatalyst Preparation Stable Initiator

[0420] Pd(PPh3)4 or Pd(Ph3P)4 = tetrakis(triphenylphosphine)palladium(0)

[0421] HOBt = 1-hydroxybenzotriazole

[0422] EDC = N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride.

[0423] Solution 1:

[0424]

[0425] Solution 2:

[0426]

[0427] Solution 3:

[0428]

[0429] Solution 4:

[0430]

[0431] Scenario 1:

[0432]

[0433] At 0 ℃, to the solution of 4-hydroxycyclohexane-1-one (10g, 1 equivalent, 88mmol) and DMAP (1.1g, 0.1 equivalent, 8.8mmol) in DCM (200mL), add benzoyl chloride (15g, 1.2 equivalents, 0.11mol) and triethylamine (13g, 18mL, 1.5 equivalents, 0.13mol). The resulting mixture was stirred at 25 ℃ for 3 hours. The required product can be detected by LCMS. The resulting mixture was diluted with water and extracted with DCM (3x 100mL). The combined organic layer was dried over anhydrous Na2SO4. After filtering, the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel and eluted with EtOAc / PE (20% gradient) to obtain 4-oxygenylidene cyclohexyl benzoate (7.4g, 34mmol, 39%), which is an oil.

[0434] 1H NMR (400 MHz, methanol-d4) δ 8.14–7.97 (m, 2H), 7.59 (dt, 1H), 7.47 (q, 2H), 5.39 (p, 1H), 2.62 (dt, 1H), 2.42 (dt, 1H), 2.19 (q, 3H), 2.01–1.69 (m, 3H).

[0435]

[0436] At -60 ° C, Br (4 g, 1 mL, 1.2 equivalents, 0.03 mol) was added to a stirred solution of triphenyl phosphite (8 g, 1.1 equivalents, 0.03 mol) in DCM (50 mL). The mixture was stirred at 25 ° C for 30 minutes. At -60 ° C, 4-oxygenylidene cyclohexyl benzoate (5 g, 1 equivalent, 0.02 mol) and triethylamine (3 g, 1.3 equivalents, 0.03 mol) were added to the mixture. The resulting mixture was stirred at 25 ° C for 16 hours. The resulting mixture was diluted with H2O (50 mL) and extracted with DCM (3 × 210 mL). The combined organic layer was washed with brine (3 × 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel and eluted with EtOAc / PE (0-25% gradient) to give 4-bromocyclohex-3-en-1-yl benzoate (5 g, 0.02 mol, 80%) as a solid.

[0437] 1H NMR(CDCl3,400MHz)δ2.00–2.17(2H,m),2.30–2.43(1H,m),2.50–2.59(1H,m),2.59–2.77(2 H,m),5.34(1H,dtd),6.01(1H,tt),7.42–7.51(2H,m),7.54–7.63(1H,m),8.02–8.09(2H,m).

[0438]

[0439] At 25 ℃ under N2 atmosphere, sodium methoxide (3.2g, 1.1 equivalents, 59mmol) was added in batches to a stirred solution of 4-bromocyclohex-3-ene-1-yl benzoate (15g, 1 equivalent, 53mmol) in MeOH (150mL). The resulting mixture was stirred for 16 hours at 25 ℃. The required product can be detected by TLC. The resulting mixture was extracted with DCM (3x80 mL). The combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel and eluted with EtOAc / PE (20% gradient), to obtain 4-bromocyclohex-3-ene-1-ol (7g, 0.04mol, 70%), which was an oil.

[0440] 1H NMR (400 MHz, methanol-d4) δ 5.92 (ddt, 1H), 3.93 (dddd, 1H), 2.72–2.28 (m, 3H), 2.16–1.69 (m, 4H).

[0441]

[0442] At 25 ℃, to 4-bromocyclohex-3-ene-1-ol (6.15g, 1 equivalent, 34.7mmol) and TMS-Cl (15.1g, 17.6mL, 4 equivalents, 139mmol) in TMS-Cl (17mL) in a stirred solution, add paraformaldehyde (1.56g, 1.5 equivalents, 52.1mmol) in batches. The resulting mixture was stirred at 25 ℃ for 16 hours. The resulting mixture was filtered, and the filter cake was washed with TMS-Cl (3x 10mL). The filtrate was concentrated under reduced pressure. The crude product is directly used in the next step without further purification.

[0443] 1H NMR (400MHz, CDCl3, 22℃) δ1.8–2.05(m,2H),2.13–2.44(m,2H),2.45–2.66(m,2H),4.12(dddd,1H),5.58(s,1H),5.94(tt,1H).

[0444]

[0445] At -78 ° C under N2 atmosphere, n-butyl lithium (0.8 g, 1.2 equivalents, 0.01 mol) was added in batches to a stirred solution of diethylamine (0.9 g, 1 mL, 1.2 equivalents, 0.01 mol) in tetrahydrofuran (24 mL). The resulting mixture was stirred at -78 ° C for 30 minutes. A solution of 1-benzyl-N-(1-phenylethyl) piperidine-4-imine (3 g, 1 equivalent, 0.01 mol) in tetrahydrofuran (15 mL) was added dropwise to the above reaction mixture. The reaction mixture was stirred for another 1 hour at -78 ° C. A solution of 1-bromo-4-(chloromethoxy) cyclohex-1-ene (3 g, 1.2 equivalents, 0.01 mol) in tetrahydrofuran (15 mL) was added dropwise to the above reaction mixture. The reaction mixture was stirred for another 1 hour at -78 ° C. The reaction was quenched by adding a saturated ammonium chloride solution and stirred for 1 hour. The obtained mixture was extracted with DCM (3x 80mL). The combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in NH4HCO3 water, 0% to 100% gradient, with 25min) to obtain 1-benzyl-3-(((4-bromocyclohex-3-ene-1-yl)oxy)methyl)piperidin-4-one (1.8g, 4.8mmol, 50%), which was an oil.

[0446] LCMS: m / z(ES+),[M+H]+=378.1.

[0447]

[0448] To a stirred solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-one (2g, 1 eq., 5mmol) in MeOH (100mL) was added ammonium formate (5g, 15 eq., 0.08mol) in batches within 15 minutes at 25°C, followed by sodium cyanoborohydride (2g, 6 eq., 0.03mol). The resulting mixture was stirred at 25°C for 3 hours. The reaction was quenched by adding a saturated solution of ammonium chloride and stirred for 15 minutes. The resulting mixture was extracted with DCM (3x 80mL). The combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in NH4HCO3 water, gradient 0% to 100% in 20 min) to give 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (1.5 g, 4.0 mmol, 70%) as an oil.

[0449] LCMS: m / z(ES+),[M+H]+=379.25.

[0450]

[0451] At -50 ° C under N2 atmosphere, to 1-benzyl-3-(((4-bromocyclohex-3-ene-1-yl)oxy)methyl)piperidin-4-amine (5g, 1 equivalent, 0.01mol) and Et3N (7g, 9mL, 5 equivalents, 0.07mol) in DCM (250mL) in a stirred solution was added trifluoromethanesulfonic anhydride (4g, 1.2 equivalents, 0.02mol) in batches. The resulting mixture was stirred at -50 ° C for 15 minutes. The reaction was quenched by adding saturated ammonium bicarbonate solution and stirred for 3 minutes. The resulting mixture was extracted with DCM (3x 50mL). The combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in NH4HCO3 water, 0% to 100%) to give the desired product (5 g, 0.01 mol, 70%) as an oil.

[0452] The mixture product (13.25 g, combined from multiple batches) was purified by achiral SFC (column: DAICEL DCpakP4VP, 5*25 cm, 5 μm; mobile phase A: CO2, mobile phase B: ACN:MEOH=4:1 (0.1% 2M NH3-MEOH); flow rate: 200 mL / min; gradient: isocratic 30% B; column temperature (°C): 35; back pressure (bar): 100; wavelength: 220 nm) to give the product (3.18 g, 4.8 mmol, 24%, 97% purity) as an oil.

[0453] LCMS: m / z(ES+),[M+H]+=513.0.

[0454] (300MHz, chloroform-d) δ7.53–7.02(m,6H),5.89(t,J=4.4Hz,1H),4.21(t,J=9.9Hz,1H),3.79–3.2 2(m,5H),2.80(d,J=11.7Hz,1H),2.67–2.30(m,4H),2.29–2.02(m,4H),2.02–1.72(m,4H).

[0455]

[0456] To a solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (13.00g, 1 eq., 34.27mmol) in DCM (150mL) was added TEA (10.40g, 14.3mL, 3 eq., 102.8mmol). Then, methanesulfonic anhydride (7.163g, 1.2 eq., 41.12mmol) was added to the mixture at 0°C. The resulting mixture was stirred at 25°C for 1.5 hours. The reaction was monitored by LCMS. The reaction was quenched by saturated NaHCO3 solution. The resulting mixture was extracted with DCM (3x 200mL). The combined organic layer was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 10% to 80% gradient in 40 min, hold at 60% for 15 min) to give the crude product (13.00 g, 28.42 mmol, 82.93%) as an oil.

[0457] The product mixture (62 g, combined from multiple batches) was purified by achiral SFC (column: DAICEL Dcpak P4VP, 4.6*50 mm, 3 um; mobile phase B: ACN:MeOH=80:20 (1% 2M NH3-MeOH)) to give the product (15 g, 33 mmol, 24.2%).

[0458] (400 MHz, CHLOROFORM-d) δ7.38–7.24 (m, 5H), 5.92 (tq, J=3.5, 1.8 Hz, 1H), 5.78 (d, J=25.8 Hz, 1H), 3.99 (d, J=17.4 Hz, 1H), 3.70–3.58 (m, 2H), 3.54 (td, J=11.2, 10.2, 5.5 Hz, 2H), 3.42 (d, J=13.2 Hz, 1H), 2.97 (s, 3H), 2.69 (s, 1H), 2.63–2.43 (m, 3H), 2.43–2.25 (m, 3H), 2.25–2.03 (m, 2H), 2.03–1.76 (m, 4H).

[0459] Scenario 2:

[0460]

[0461] To a solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (8.02 g, 1 eq., 21.1 mmol) and N-ethyl-N-isopropylpropane-2-amine (8.20 g, 3 eq., 63.4 mmol) in DCM (80 mL) was added di-tert-butyl dicarbonate (4.61 g, 1 eq., 21.1 mmol). The resulting mixture was stirred at 25 °C for 2 hours. The crude product was purified by flash chromatography on silica gel and eluted with PE / EtOAc (0-12% gradient) to give 4.5 g of crude product as an oil.

[0462] The above mixture was purified by achiral SFC rep-achiral-SFC (column: Viridis BEH 2-EP, 100*4.6 mmm, 5 um; mobile phase B: MeOH (1% 2M NH3-MeOH); flow rate: 4 mL / min; gradient: isocratic 5% B) to give the product (1.79 g, 3.73 mmol, 17.9%) as an oil.

[0463] LCMS: m / z(ES+),[M+H]+=481.1.

[0464] 1H NMR (400 MHz, CHLOROFORM-d) δ7.33 (s, 5H), 5.91 (s, 1H), 5.68 (s, 1H), 3.83 (d, J = 47.2 Hz, 2H), 3.64–3.33 (m, 3H), 2.76–2.23 (m, 6H), 2.14 (d, J = 17.9 Hz, 2H), 2.03 (s, 1H), 1.97–1.73 (m, 3H), 1.46 (s, 9H).

[0465]

[0466] To a solution of vinyl bromide (1.79 g, 1 eq., 3.73 mmol) and (1-methyl-1H-indazole-5-yl)boronic acid (723 mg, 1.1 eq., 4.11 mmol) in 1,4-dioxane (30 mL) and water (6.0 mL) was added NaCO (1.19 g, 3 eq., 11.2 mmol) and PdCl(dppf).CHCl (305 mg, 0.1 eq., 373 μmol). After stirring at 80 °C under a nitrogen atmosphere for 22 hours, the resulting mixture was diluted with HO (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (3 x 200 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC with EtOAc / PE (2 / 1) to give the product (1.68 g, 3.17 mmol, 84.8%) as an oil.

[0467] LCMS: m / z(ES+),[M+H]+=531.5.

[0468] 1H NMR (400MHz, chloroform-d) δ7.96 (dd, J=2.0, 1.0Hz, 1H), 7.77–7.64 (m, 1H), 7.51 (dd ,J=8.8,1.7Hz,1H),7.41–7.25(m,7H),6.01(s,1H),4.09(s,3H),3.94(d,J= 25.8Hz,1H),3.80(s,1H),3.51(s,6H),2.72–2.50(m,4H),2.28(d,J=9.2Hz, 2H),2.07(s,1H),1.86(s,2H),1.65(s,2H),1.51–1.22(m,9H),1.05(s,1H).

[0469]

[0470] Under nitrogen atmosphere, Pd / C (1.65g, 10% Wt, 0.5 equivalent, 1.55mmol) and palladium (2+) dihydroxide (2.18g, 10% wt, 0.5 equivalent, 1.55mmol) were added to a solution of tert-butyl olefin (1.65g, 1 equivalent, 3.11mmol) and 1,1,2-trichloroethane (498mg, 347 μL, 1.2 equivalents, 3.73mmol) in i-PrOH (40mL) under nitrogen atmosphere. The resulting mixture was hydrogenated at room temperature for 4 hours using a hydrogen balloon under a hydrogen atmosphere. The crude reaction mixture was filtered through a diatomaceous earth pad and concentrated under reduced pressure to obtain a crude product. The crude product was directly used in the next step without further purification.

[0471] LCMS: m / z(ES+),[M+H]+=443.2.

[0472]

[0473] To a solution of amine (100.0 mg, 1 eq., 225.9 μmol) and 3-bromopyridazine (71.84 mg, 2 eq., 451.9 μmol) in DMSO (5 mL) was added Cs2CO3 (147.2 mg, 2 eq., 451.9 μmol) and PEPPSI-Pd (19.00 mg, 0.1 eq., 22.59 μmol). The resulting mixture was stirred at 120 ° C for 4 hours under a nitrogen atmosphere. A total of 12 reactions were carried out in parallel. The resulting mixture was extracted with ethyl acetate (3x200 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (MeOH / DCM=1 / 15) to obtain the product (620 mg, 1.19 mmol, 47.7%) as an oil.

[0474] LCMS: m / z(ES+),[M+H]+=521.2.

[0475]

[0476] To a stirred solution of Boc protected amine (200 mg, 1 eq., 384.1 μmol) in 1,4-dioxane (6 mL) was added HCl (70 mg, 480.1 μL, 4 moles, 5 eq., 1.921 mmol) at room temperature. The mixture solution was stirred at room temperature for 1 hour. The resulting solution was evaporated under reduced pressure to give the product amine (150.0 mg, 356.7 μmol, 92.85%) as a solid HCl salt. The crude product was used directly in the next step without further purification.

[0477] LCMS: m / z(ES+),[M+H]+=421.30.

[0478] Solution 3:

[0479]

[0480] To a solution of vinyl bromide (1.50 g, 1 eq., 2.93 mmol) and Pd(Ph3P)4 (339 mg, 0.1 eq., 293 μmol) in 1,4-dioxane (20 mL) and water (4.0 mL) was added Cs2CO3 (2.87 g, 3 eq., 8.80 mmol) and (1-methyl-1H-indazole-6-yl)boric acid (671 mg, 1.3 eq., 3.81 mmol). After stirring for 3 hours at 80 °C under a nitrogen atmosphere, the resulting mixture was diluted with H2O (20 mL) and extracted with EtOAc (3x50 mL). The combined organic layers were washed with brine (3x20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC with EtOAc / PE (5% TEA) to give the product (930 mg, 1.65 mmol, 56.4%) as a solid.

[0481] LCMS: m / z(ES+),[M+H]+=563.25.

[0482]

[0483] Under nitrogen atmosphere, Pd(OH)2(37.4mg, 0.5 equivalent, 267μmol), Pd / C(28.4mg, 0.5 equivalent, 267μmol) and 1,1,2-trichloroethane(142mg, 2 equivalents, 1.07mmol) were added to a solution of olefin(300mg, 1 equivalent, 533μmol) in i-PrOH(60mL). The resulting mixture was hydrogenated at room temperature for 3 hours using a hydrogen balloon under a hydrogen atmosphere. The resulting mixture was filtered through a diatomaceous earth pad and concentrated under reduced pressure to obtain a crude product as the HCl salt. The crude product was used directly in the next step.

[0484] LCMS: m / z(ES+),[M+H]+=475.10.

[0485]

[0486] To a solution of vinyl bromide (2.00 g, 1 eq., 4.37 mmol) in 1,4-dioxane (20 mL) was added (1-methyl-1H-indazole-5-yl)boric acid (846 mg, 1.1 eq., 4.81 mmol), K2CO3 (1.81 g, 3 eq., 13.1 mmol), water (4.0 mL) and Pd(PPh3)4 (505 mg, 0.1 eq., 437 μmol) at room temperature. The mixture solution was stirred at 80 ° C for 2 hours under N2 atmosphere. The reaction was monitored by LCMS. The mixture was diluted with water and extracted with EA. The combined organic phase was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 65% gradient in 30 min; detector, UV 254 nm) to give the desired product (1.70 g, 3.34 mmol, 76.4%) as an oil.

[0487] LCMS: m / z(ES+),[M+H]+=509.3.

[0488]

[0489] At room temperature, 1,1,2-trichloroethane (892 mg, 621 μL, 2 equivalents, 6.68 mmol), Pd(OH)2 (1.41 g, 10% wt, 0.3 equivalents, 1.00 mmol) and Pd / C (1.07 g, 10% wt, 0.3 equivalents, 1.00 mmol) were added to a solution of olefin (1.70 g, 1 equivalent, 3.34 mmol) in i-PrOH (5 mL). The mixture was stirred at 20 ° C for 32 hours under H2 atmosphere. The reaction was monitored by LCMS. The solution was filtered through a diatomaceous earth pad and concentrated under reduced pressure to obtain the product (1.40 g, 3.06 mmol, 92%).

[0490] LCMS: m / z(ES+), [M+Na]+=421.25.

[0491]

[0492] To a solution of vinyl bromide (2.00 g, 1 eq., 4.37 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (1.67 g, 1.5 eq., 6.56 mmol) and KOAc (858 mg, 2 eq., 8.74 mmol) in dioxane (20 mL) was added PdCl2(dppf)-CH2Cl2 adduct (179 mg, 0.05 eq., 219 μmol). The resulting mixture was stirred at 100 °C for 4 hours under a nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with EA (3x10 mL). The filtrate was concentrated under reduced pressure. The crude product (1.8 g) was used directly in the next step without further purification.

[0493] LCMS: m / z (ES+), [M+H]+=505.

[0494]

[0495] Under nitrogen atmosphere, NaCO (347 mg, 3 eq., 3.27 mmol) and PdCl (dppf). CHCl adduct (44.5 mg, 0.05 eq., 54.5 μmol) were added to a solution of borate (550 mg, 1 eq., 1.09 mmol) and 5-bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine (231 mg, 1 eq., 1.09 mmol) in 1,4-dioxane (8 mL) and H2O (0.2 ml). The resulting mixture was stirred at 80 ° C for 2 hours. The resulting mixture was filtered and the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 55% to 65% gradient, in 10 min; detector, UV 254nm) to give the crude product (220mg) as a solid. The crude product was purified by preparative TLC (EA / PE=4 / 1, 5% TEA) to give the product (180mg, 353μmol, 32.4%) as a solid.

[0496] LCMS: m / z(ES+),[M+H]+=510.0.

[0497]

[0498] Under nitrogen atmosphere, Pd / C (150 mg, 10% wt, 0.479 eq., 141 μmol) was added to a solution of olefin (150 mg, 1 eq., 294 μmol) and Boc2O (128 mg, 135 μL, 2 eq., 589 μmol) in i-PrOH (18 mL). The resulting mixture was hydrogenated at room temperature for 30 hours using a hydrogen balloon under a hydrogen atmosphere. The reaction mixture was filtered through a diatomaceous earth pad and concentrated under reduced pressure to obtain a crude product. The crude product was directly used in the next step without further purification.

[0499] LCMS: m / z (ES+), [M+H]+=522.

[0500]

[0501] A solution of N-Boc protected amine (150 mg, 1 eq., 288 μmol) and HCl in 1,4-dioxane (2 mL) was stirred at 25 °C for 1.5 hours. The resulting mixture was concentrated under reduced pressure to give a crude product. The crude product was lyophilized to give the product amine (110 mg, 240 μmol, 83.5%) as a solid as the HCl salt.

[0502] LCMS: m / z (ES+), [M+H]+=422.

[0503]

[0504] To a solution of vinyl bromide (1.68 g, 1 eq., 3.29 mmol) and 7-fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (1 g, 1 eq., 4 mmol) and PdCl2(dppf).CH2Cl2 adduct (240 mg, 0.1 eq., 329 μmol) and Na2CO3 (1.04 g, 3 eq., 9.86 mmol) in dioxane (10 mL) and water (2 mL). The resulting mixture was stirred at 80 ° C for 4 hours. The resulting mixture was extracted with ethyl acetate / water (3x100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with EtOAc / PE (0-100% gradient) to give the product (3.17 g, 5.46 mmol, 60%).

[0505] LCMS: m / z(ES+),[M+H]+=581.45.

[0506]

[0507] Pd(OH)2 (2.10 g, 4 eq., 14.9 mmol) and 1,1,2-trichloroethane (499 mg, 347 μL, 1 eq., 3.74 mmol) and Pd / C (1.99 g, 5 eq., 18.7 mmol) were added to a solution of olefin (2.17 g, 1 eq., 3.74 mmol) in i-PrOH (10 mL). The resulting mixture was stirred at 25 ° C for 3 hours. The resulting mixture was filtered and the filter cake was washed with [isopropanol + hydrochloric acid (10%)] (3x100 ML). The filtrate was concentrated under reduced pressure to give the product (1.92 g, 2.7 mmol, 73%, 73% purity).

[0508] LCMS: m / z(ES+),[M+H]+=493.10.

[0509] Solution 4:

[0510]

[0511] To a test tube equipped with an airtight screw cap was added vinyl bromide (100 mg, 1 eq, 219 μmol), tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole-1-carboxylate (97.8 mg, 1.3 eq, 284 μmol), Na2CO3 (69.5 mg, 3 eq, 656 μmol), dioxane (2 mL) and H2O (0.7 mL), followed by PdCl2(dppf) (16.0 mg, 0.1 eq, 21.9 μmol). The resulting mixture was stirred at 80°C for 1 hour. The reaction mixture was extracted with DCM (3x100 mL) and water. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and purified by thin layer chromatography (PE:EA=1:3) to give the product (70 mg, 0.10 mmol, 47%, 87% purity) as a solid.

[0512] LCMS: m / z(ES+),[M+H]+=595.30.

[0513] 1H NMR (400MHz, chloroform-d) δ1.24-1.32(m,2H),1.73(s,9H),1.89(s,3H),2.07(s,1H),2.31(s,5H),2.58(s,3H),2.65(s,3H),2.93(d,3H), 3.43(s,1H),3.51(s,1H),3.69(s,3H),4.15(q,1H),6.07(s,1H),7.33(s,6H),7.43(dd,1H),7.72(d,1H),8.05(s,1H),8.41(s,1H).

[0514]

[0515] To a test tube equipped with a gas-tight screw cap was added tert-butyl 5-(4-(((3R,4S)-1-benzyl-4-(methylsulfonamido)piperidin-3-yl)methoxy)cyclohex-1-en-1-yl)-1H-benzo[d]imidazole-1-carboxylate (150 mg, 1 eq, 252 μmol), H2 (5.09 mg, 10 eq, 2.52 mmol), i-PrOH (4 mL) and then Pd / C (8.05 mg, 0.3 eq, 75.7 μmol). The resulting mixture was stirred at 25 °C for 12 hours. At this time, LCMS analysis indicated that the reaction was complete, and the reaction mixture was then filtered through a pad of celite and rinsed thoroughly with dichloromethane. The filtrate was concentrated under reduced pressure and the crude material was purified by thin layer chromatography (PE:EA=1:2) to give the product amine (60 mg, 0.12 mmol, 47%) as a solid. LCMS: m / z(ES+),[M+H]+=507.25.

[0516] 1H NMR (400MHz, chloroform-d) δ 0.04-0.13 (m, 1H), 0.09 (s, 12H), 1.22-1.33 (m, 5H), 1.30 (s, 1H), 1.39-1.53 ​​(m, 1H), 1.72 (d, 11H), 1.79 (d, 1H), 1.90 (s, 1H), 1.94-2.14 (m, 2H), 2.22 (d, 2H), 2.63-2. 74(m,1H),2.83-3.15(m,2H),3.01(s,2H),3.59-3.74(m,2H),3.78(s,1H),3.93(q,1H),6.06 (s,1H),6.19(s,0H),7.26-7.37(m,1H),7.71(dd,1H),7.86-7.93(m,1H),8.35-8.43(m,1H).

[0517]

[0518] To a stirred mixture of vinyl bromide (3.60 g, 1 eq., 7.87 mmol) and tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate (2.84 g, 1.05 eq., 8.26 mmol) and NaCO (139 mg, 3 eq., 1.31 mmol) in 1,4-dioxane (32 mL) and HO (0.4 ml) was added PdCl(dppf) (576 mg, 0.1 eq., 787 μmol) under nitrogen atmosphere. The resulting mixture was stirred at 80 °C for 2 hours. The resulting mixture was extracted with ethyl acetate (3x20 mL). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 90% to 100% gradient in 20 min; detector, UV 254 nm) to give a mixture. The mixture was concentrated under reduced pressure to give the crude product (4.3 g) as a solid. The material was repurified by flash chromatography on silica gel eluting with EtOAc / PE (100% gradient) to give the product (2.56 g, 4.30 mmol, 54.7%) as a solid. LCMS: m / z (ES+), [M+H]+=595.

[0519]

[0520] To a solution of tert-butyl olefin (1.500 g, 1 eq., 2.522 mmol) in i-PrOH (170 mL) was added Pd / C (1.5 g, 10% wt, 0.56 eq., 1.4 mmol) under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 5 days using a hydrogen balloon under hydrogen atmosphere, filtered through a celite pad and concentrated under reduced pressure to give a crude product (1 g). LCMS: m / z (ES+), [M+H]+=507.

[0521]

[0522] To a solution of vinyl bromide (250 mg, 1 eq., 489 μmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (143 mg, 1.2 eq., 587 μmol) in water (5 mL), 1,4-dioxane (20 mL) was added NaCO (155 mg, 3 eq., 1.47 mmol) and PdCl (dppf) (200 mg, 0.5 eq., 244 μmol). The resulting mixture was stirred at 80 °C for 8 hours. The resulting mixture was extracted with dichloromethane (3x20 mL). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (EA / PE=1 / 1) to give the product (100 mg, 182 μmol, 37.3%) as a solid. LCMS: m / z (ES+), [M+H]+=549.20.

[0523]

[0524] Pd / C (135 mg, 5 equivalents, 1.27 mmol) was added to a solution of olefin (139 mg, 1 equivalent, 253 μmol) in i-PrOH (20 mL). The resulting mixture was stirred at 25 ° C for 8 hours under a hydrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure to the product amine (68 mg, 148 μmol, 58.7%) as a solid.

[0525] LCMS: m / z(ES+),[M+H]+=461.35.

[0526]

[0527] To a stirred mixture of vinyl bromide (300 mg, 1 eq., 656 μmol) and 3-hydroxy-2,3-dimethylbutane-2-yl hydrogen (1-methyl-1H-benzo [d] imidazole-6-yl) borate (217 mg, 1.2 eq., 787 μmol) in 1,4-dioxane (15 mL) and water (0.8 mL) was added CsCO (641 mg, 3 eq., 1.97 mmol) and Pd(PhP) (152 mg, 0.2 eq., 131 μmol) at room temperature under a nitrogen atmosphere. The final reaction mixture was stirred at 80 ° C for 3 hours. The resulting mixture was diluted with H2O (50 mL) and extracted with EtOAc (3x50 mL). The combined organic layers were washed with brine (1x50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: 8 mmol NH4HCO3, mobile phase B: ACN, 10% to 90% gradient in 45 min) to give the product (180 mg, 354 μmol, 54.0%) as an oil.

[0528] LCMS: m / z (ES+), [M+H]+=509.

[0529]

[0530] To a solution of olefin (180 mg, 1 eq., 354 μmol) in i-PrOH (10 mL) was added Pd(OH)2 (24.8 mg, 0.5 eq., 177 μmol) and ammonium formate (223 mg, 176 μL, 10 eq., 3.54 mmol) under a nitrogen atmosphere. The resulting mixture was stirred at 60 °C for 1 hour. After filtration, the filtrate was concentrated under reduced pressure to give the crude product (130 mg, 309 μmol, 87.4%) as a solid.

[0531] LCMS: m / z (ES+), [M+H]+=421.

[0532]

[0533] Pd(Ph3P)4(0.51g, 0.2 eq., 0.44mmol) and Cs2CO3(2.1g, 3 eq., 6.6mmol) were added to a solution of vinyl bromide (1.0g, 1 eq., 2.2mmol) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole (0.68g, 1.2 eq., 2.6mmol) in 1,4-dioxane (5mL) and water (1mL). The resulting mixture was stirred at 80°C for 3 hours under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was extracted with ethyl acetate (3x50 mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (MeOH / DCM=1 / 10) to give the product (678 mg, 1.2 mmol, 55%, 90% purity) as a semisolid. LCMS: m / z (ES+), [M+H]+=509.30.

[0534]

[0535] Pd / C (400 mg, 10% wt, 0.478 eq., 376 μmol) and Pd(OH)2 (400 mg, 3.62 eq., 2.85 mmol) were added to a solution of olefin (400 mg, 1 eq., 786 μmol) and 1,1,2-trichloroethane (210 mg, 2 eq., 1.57 mmol) in ethyl acetate (18 mL). The resulting mixture was hydrogenated at room temperature for 16 hours using a hydrogen balloon under a hydrogen atmosphere. The reaction was monitored by LCMS. The mixture was filtered through a diatomaceous earth pad and concentrated under reduced pressure to give a crude product (330 mg).

[0536] LCMS: m / z(ES+),[M+H]+=421.20.

[0537] Compound 1:

[0538]

[0539] TEA (280 mg, 385 μL, 2 equivalents, 2.76 mmol) was added to a solution of amine (700 mg, 1 equivalent, 1.38 mmol) and trifluoromethanesulfonic acid pyridin-2-yl ester (471 mg, 1.5 equivalents, 2.07 mmol) in DMSO (13 mL). The resulting mixture was stirred at 120 ° C for 5 hours. The resulting mixture was extracted with dichloromethane (3x15 mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 45% to 55% gradient, with 10 min) to obtain an isomeric mixture of the product (330 mg, 565 μmol, 40.9%) as a solid.

[0540] The isomeric mixture was separated by chiral preparative HPLC (column: CHIRALPAK IG, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: MeOH:DCM=1:1; flow rate: 20 mL / min; gradient: 45% B to 45% B in 19 min) to give N-((3R,4S)-3-((((1s,4S)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (101 mg, 209 μmol, 34%) as a solid.

[0541] LCMS: m / z (ES+), [M+H]+=484.

[0542] 1H NMR (400 MHz, methanol-d4) δ 8.07 (ddd, J = 5.1, 2.0, 0.9 Hz, 1H), 7.97 (d, J = 1.0 Hz, 1H), 7.62–7.58 (m, 1H), 7.55–7.43 (m, 2H), 7.33 (dd, J = 8.7, 1.6 Hz, 1H), 6.88 (dt, J = 8.7, 0.9 Hz, 1H), 6.63 (ddd, J = 7.1, 5.0, 0.8 Hz, 1H), 3.88 (dq, J = 12.0, 6.7, 6.1 Hz, 2H), 3.78 (dd, J = 13.3, 6.8 Hz, 1H), 3.69 (dd, J = 9.4, 5.9 Hz, 1H), 3.64 (d, J = 4.0 Hz, 1H), 3.61–3.54 (m, 2H), 3.50–3.42 (m, 1H), 3.37 (s, 1H), 3.06 (s, 3H), 2.72–2.64 (m, 1H), 2.30 (dq, J = 10.7, 7.3, 5.5 Hz, 1H), 2.09 (d, J = 12.9 Hz, 2H), 1.97–1.82 (m, 4H), 1.72–1.56 (m, 4H).

[0543] Compound 2:

[0544]

[0545] To a solution of amine (80 mg, 1 eq., 0.17 mmol) in DMSO (4 mL) was added TEA (35 mg, 48 μL, 2 eq., 0.35 mmol) and 1,1,1-trifluoro-N-(pyridin-2-yl)methanesulfonamide (59 mg, 1.5 eq., 0.26 mmol). The resulting mixture was stirred at 120 ° C for 8 hours. The reaction was monitored by LCMS and the crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 0% to 55% gradient, with 20 minutes and holding the gradient for 30 minutes; detector, UV254 nm) to obtain an isomeric mixture of the product (17 mg, 32 μmol, 18%) as a solid. The above 17 mg material was subjected to reverse phase flash chromatography (column: XBridge Prep OBD C18 column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 40% B to 68% B, 8 min, 68% B) Repurify to give a racemic mixture of N-((3R,4S)-3-((((1s,4S)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)-1,1,1-trifluoromethanesulfonamide and N-((3R,4S)-3-((((1s,4S)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)-1,1,1-trifluoromethanesulfonamide (4.1 mg, 7.6 μmol, 24%) as a solid.

[0546] LCMS: m / z(ES+),[M+H]+=538.1.

[0547] 1H NMR (400MHz, chloroform-d) δ8.19 (d, J = 5.1Hz, 1H), 8.04 (s, 1H), 7.87 (d, J = 6.4Hz, 1H), 7.60 (s, 1H), 7.54 (s, 1H), 7.44 (d, J = 8.6Hz, 1H), 7.31 (d, J = 8.6Hz, 1H), 6.69 (s, 2H), 4.31 ( d,J=13.7Hz,1H),4.06(dq,J=22.6,13.0Hz,3H),3.78(s,1H),3.68(s,1H),3.18(d,J =52.7Hz, 2H), 2.66 (s, 1H), 2.53 (d, J = 8.3Hz, 1H), 2.09 (s, 4H), 1.76 (d, J = 9.1Hz, 6H).

[0548] Compound 3:

[0549]

[0550] To a solution of amine (300mg, 1 equivalent, 713μmol) and Et3N (144mg, 199μL, 2 equivalents, 1.43mmol) in DMSO (5mL) was added trifluoromethanesulfonic acid pyridin-2-yl ester (243mg, 1.5 equivalents, 1.07mmol). The resulting mixture was stirred at 120°C for 12 hours. The resulting mixture was extracted with ethyl acetate (3x100 mL). The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (EA) to obtain an isomeric mixture of the product (135mg, 271μmol, 38.0%), which was solid. The product (135 mg) was purified by preparative HPLC (column: XBridge Prep OBD C18 column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 39% B to 63% B, in 8 min, 63% B) to obtain two peaks. The more polar product (50 mg) was purified by chiral preparative HPLC (column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 60:40) to give N-((3R, 4S)-3-((((1s, 4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (11.9 mg, 23.9 μmol, 24%) as a solid.

[0551] LCMS: m / z (ES+), [M+H]+=498.

[0552] 1H NMR (400MHz, methanol-d4) δ8.15–8.05(m,1H),7.92(d,J=0.9Hz,1H),7.61–7.54(m ,2H),7.50–7.44(m,1H),7.35(dd,J=8.7,1.6Hz,1H),6.92–6.85(m,1H),6.71 –6.9(m,1H),4.05(s,3H),3.87–3.78(m,2H),3.77–3.48(m,6H),3.05(s,3H) ,2.70–2.61(m,1H),2.27–2.16(m,3H),2.00–1.82(m,4H),1.66–1.35(m,5H).

[0553] Compound 4:

[0554]

[0555] To a solution of amine (50 mg, 1 equivalent, 99 μmol) and 1-fluorocyclobutane-1-carboxylic acid (17 mg, 1.5 equivalents, 0.15 mmol) in DCM (2 mL) was added N-ethyl-N-isopropylpropane-2-amine (38 mg, 3 equivalents, 0.30 mmol), N, N-dimethylpyridine-4-amine (1.2 mg, 0.1 equivalent, 9.9 μmol), 1H-benzo [d] [1,2,3] triazole-1-ol hydrate (23 mg, 1.5 equivalents, 0.15 mmol) and 3-(((ethylimino)methylene)amino)-N, N-dimethylpropane-1-amine (23 mg, 1.5 equivalents, 0.15 mmol). The resulting mixture was stirred at 25 ° C for 2 hours. The reaction was monitored by LCMS. The resulting mixture was extracted with dichloromethane (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure to give an isomer mixture of the product (58 mg, 96 umol, 97%) as an oil.

[0556] LCMS: m / z(ES+),[M+H]+=607.55.

[0557] To a stirred mixture of the above tert-butyl 5-(4-(((3R, 4S)-1-(1-fluorocyclobutane-1-carbonyl)-4-(methylsulfonamido)piperidin-3-yl)methoxy)cyclohexyl)-1H-indazole-1-carboxylate (78 mg, 1 eq., 0.13 mmol) in DCM (5 mL) was added a solution of TFA (1 ml) at 25 °C under a nitrogen atmosphere. The resulting mixture was stirred at 25 °C for 0.5 hours. The resulting mixture was extracted with dichloromethane (3x10 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: X Bridge Shield RP18OBD column, 30*150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 38% B to 48% B, 8 min, 48% B), followed by chiral preparative HPLC (column: CHIRALPAK IC, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: EtOH:DCM=1:1--HPLC; flow rate: 20 mL / min; gradient: 40% B to 40% B, 14 min) to give the desired isomer N-((3R,4S)-3-((((1s,4R)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(1-fluorocyclobutane-1-carbonyl)piperidin-4-yl)methanesulfonamide (6 mg, 0.01 mmol, 30%, 99.5% purity) as a solid.

[0558] LCMS: m / z(ES+),[M+H]+=507.45.

[0559] 1H NMR (400MHz, chloroform-d) δ8.09(s,1H),7.66(s,1H),7.49(d,J=8.6Hz,1H),7.37(d,J=8.7Hz,1H),6.58(d,J=5.2Hz,1H),4.06–3.83(m,2H),3.82–3.5 9(m,5H),3.46(dd,J=56.8,13.4Hz,2H),3.01(s,3H),2.72(d,J=30.5Hz ,3H),2.37(d,J=58.6Hz,3H),2.17–1.86(m,6H),1.72(d,J=46.7Hz,6H).

[0560] Compound 5:

[0561]

[0562] Pyridine (87 mg, 89 μL, 8 equivalents, 1.1 mmol) and triphosgene (20 mg, 0.5 equivalents, 69 μmol) were added to a solution of amine (70 mg, 1 equivalent, 0.14 mmol) in DCM (2 mL). The resulting mixture was stirred at 25 ° C for 2 hours. The solvent was removed and MeOH (2 ml) was added to the mixture. The resulting mixture was stirred for 0.5 hours at 80 ° C and the reaction mixture was monitored by LCMS. The crude product was purified by reverse phase chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 95% gradient, with 30 min; detector, UV 254 nm) to obtain an isomeric mixture of the product (78 mg, 0.14 mmol, 100%) as a solid.

[0563] LCMS: m / z(ES+),[M+H]+=565.20.

[0564] The above mixture was purified by preparative HPLC (column: XSelect CSH Prep C18 OBD column, 19*250 mm, 5 μm; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 30 mL / min; gradient: 37% B to 48% B, 7 min, 48% B), followed by preparative chiral HPLC (column: DZ-CHIRALPAK IF-3, 4.6*50mm, 3.0μm; mobile phase A: Hex (0.2% DEA):(MeOH:DCM=1:1)=80:20) was purified to obtain (3R,4S)-3-((((1s,4R)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-4-(methylsulfonamido)piperidine-1-carboxylic acid methyl ester (13.6 mg, 29.1μmol, 39%, 99.5% purity) as a solid.

[0565] LCMS: m / z(ES+),[M+H]+=465.35.

[0566] 1H NMR (400MHz, chloroform-d) δ8.08 (s, 1H), 7.66 (s, 1H), 7.49 (d, J = 8.6Hz, 1H), 7.41–7. 35(m,1H),6.48(s,1H),3.80(dd,J=11.2,7.0Hz,4H),3.72(s,3H),3.67(s,2H ),3.45–3.24(m,2H),3.00(s,3H),2.66(d,J=15.1Hz,1H),2.26(s,1H),2.09( d, J=13.9Hz, 2H), 1.96 (dd, J=9.0, 4.4Hz, 1H), 1.89–1.72 (m, 5H), 1.63 (s, 2H).

[0567] Compound 6:

[0568]

[0569] Amine, TEA (24 mg, 33 μ L, 2 equivalents, 0.24 mmol) and DMSO (2 mL) were added to a test tube equipped with an airtight screw cap, followed by trifluoromethanesulfonic acid pyridin-2-yl ester (40 mg, 1.5 equivalents, 0.18 mmol). The resulting mixture was stirred at 120 ° C for 12 hours. The reaction mixture was extracted with DCM (3x100 mL) and water. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure and purified by thin layer chromatography (PE: EA = 1: 1) to obtain an isomeric mixture of the product (35 mg, 72 μ mol, 61%), which was a solid. The compound was re-purified by preparative HPLC (column: XBridge Prep C18 OBD column, 30*50 mm, 5 μm 13 nm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN) to give N-((3R,4S)-3-((((1s,4S)-4-(1H-benzo[d]imidazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (3.6 mg, 7.1 μmol, 17%) as a solid.

[0570] LCMS: m / z(ES+),[M+H]+=484.20.

[0571] 1H NMR (400MHz, chloroform-d) δ1.28(s,1H),1.55-1.67(m,3H),1.78(s,4H),1.83(d,1H),2.05(s,4 H),2.09(s,1H),2.40(s,2H),2.69(s,2H),3.04(s,3H),3.44(dd,1H),3.64(s,1H),3.68( dd,1H),3.83-3.88(m,1H),3.95(q,2H),4.06(dd,1H),6.52(d,1H),6.60-6.67(m,1H),6 .69(d,1H),7.19(d,1H),7.45-7.54(m,1H),7.58-7.67(m,2H),8.05(s,1H),8.19(d,1H).

[0572] Compound 7:

[0573]

[0574] To a solution of amine (110 mg, 1 eq., 261 μmol) and pyridin-2-yl trifluoromethanesulfonate (88.9 mg, 1.5 eq., 391 μmol) in DMSO (3 mL) was added TEA (79.2 mg, 109 μL, 3 eq., 783 μmol). The resulting mixture was stirred at 120 °C for 6 hours. The crude product was purified by reverse phase chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 40% to 55% gradient, in 30 min; detector, UV 254 nm) to give an isomeric mixture of the product (50 mg, 0.10 mmol, 39%) as a solid.

[0575] The crude product was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 50:50) to give N-((3R, 4S)-3-((((1s, 4S)-4-(1-methyl-1H-pyrazolo[3,4-c]pyridin-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (18 mg, 36 μmol, 36%) as a solid.

[0576] LCMS: m / z (ES+), [M+H]+=499.

[0577] 1H NMR(400MHz, DMSO-d6)δ9.07(d,J=1.1Hz,1H),8.09–8.04(m,2H),7.51–7.43(m,2H),7. 22(d,J=7.8Hz,1H),6.82(d,J=8.7Hz,1H),6.56(dd,J=7.1,4.9Hz,1H),4.15(s,3H),3.7 3(dt,J=14.1,8.5Hz,2H),3.61–3.47(m,6H),2.99(s,3H),2.81(ddd,J=11.5,8.1,3.7H z,1H),2.12(d,J=29.1Hz,2H),1.99–1.82(m,5H),1.78–1.50(m,7H),1.36–1.22(m,1H).

[0578] Compound 8:

[0579]

[0580] To a solution of amine (100 mg, 1 eq., 238 μmol) and triethylamine (48.1 mg, 66.3 μL, 2 eq., 476 μmol) in DMSO (2 mL) was added trifluoromethanesulfonic acid pyridin-2-yl ester (81.0 mg, 1.5 eq., 357 μmol). The resulting mixture was stirred at 120 ° C for 3 hours. The reaction solution was concentrated under reduced pressure to give a crude product. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 35% to 65% gradient) to give a racemic mixture of the product (4.9 mg, 9.8 μmol, 16%) as a solid.

[0581] LCMS: m / z(ES+),[M+H]+=498.25.

[0582] 1H NMR (400MHz, methanol-d4) δ8.10–8.04(m,1H),8.07(s,1H),7.57–7.43(m,3H),7.27 (dd,1H),6.92–6.85(m,1H),6.62(ddd,1H),3.90(s,3H),3.86(d,1H),3.77(dd ,1H),3.69(dd,1H),3.64(s,1H),3.62–3.54(m,2H),3.54–3.43(m,1H),3.06( s,3H),2.71(t,1H),2.31(s,1H),2.09(d,2H),2.01–1.81(m,4H),1.66(q,4H).

[0583] Compound 9:

[0584]

[0585] To a solution of amine (130 mg, 1 equivalent, 309 μmol) and trifluoromethanesulfonic acid pyridin-2-yl ester (84.3 mg, 1.2 equivalents, 371 μmol) in DMSO (5 mL) was added TEA (93.8 mg, 129 μL, 3 equivalents, 927 μmol). After stirring for 3 hours at 120 ° C under a nitrogen atmosphere, the resulting mixture was diluted with H2O (50 mL) and extracted with EtOAc (3x20 mL). The combined organic layer was washed with brine (1x50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: 8mmol NH4HCO3, mobile phase B: ACN, 20% to 70% gradient, with 30min; detector, UV 254nm) to obtain an isomeric mixture of the product (small peak 5mg, main peak 18mg). The isomeric mixture (18mg) was purified by preparative HPLC using the following conditions (column: XBridge Prep OBD C18 column, 30*150mm, 5μm; mobile phase A: water (10mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60mL / min; gradient: 28% B to 58% B, with 8min, 58% B) was purified to give an enantiomeric mixture of N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-benzo[d]imidazol-6-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide and N-((3S,4R)-3-((((1s,4S)-4-(1-methyl-1H-benzo[d]imidazol-6-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (7.2 mg, 14 μmol, 40%) as a solid.

[0586] LCMS: m / z (ES+), [M+H]+=498.

[0587] 1H NMR(400MHz, methanol-d4)δ8.10–8.02(m,2H),7.61–7.48(m,2H),7.46(d,1H),7 .19(dd,,1H),6.91-6.84(m,1H),6.70-6.59(m,1H),3.89(s,5H),3.82–3.4 3(m,6H),3.06(s,3H),2.81–2.68(m,1H),2.38-2.29(m,1H),2.10(d,2H),2 .01-1.85(m,4H),1.76-1.58(m,4H),1.41–1.23(m,2H),0.96–0.86(m,1H).

[0588] Compound 10:

[0589]

[0590] To a solution of amine (700 mg, 1 equivalent, 1.48 mmol) and 2-bromopyridine (466 mg, 2 equivalents, 2.95 mmol) in 1,4-dioxane (36 mL) was added CsCO (1.44 g, 3 equivalents, 4.43 mmol) and Pd-PEPPSI-Ipent (124 mg, 0.1 equivalent, 148 μmol). After stirring overnight at 100 ° C under a nitrogen atmosphere, the resulting mixture was diluted with H O (30 mL) and extracted with EtOAc (3x150 mL). The combined organic layer was washed with brine (3x10 mL) and dried over anhydrous Na SO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: 0.9 g / L NH4HCO3 to water, mobile phase B: ACN, 5% to 95% gradient in 30 min) to give an isomeric mixture of the product (550 mg, 997 μmol, 67.6%) as a solid.

[0591] The above isomer mixture was purified by chiral preparative HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): EtOH = 80:20; flow rate: 1 mL / min; gradient: 0% B to 0% B) to give 1,1,1-trifluoro-N-((3R,4S)-3-((((1s,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (98.5 mg, 174 μmol, 29.1%) as a solid.

[0592] LCMS: m / z(ES+),[M+H]+=552.25.

[0593] 1H NMR(400MHz, methanol-d4)δ8.09–8.03(m,1H),7.92(d,1H),7.59–7.49(m,2H),7.47( d,1H),7.36(d,1H),6.91(d,1H),6.65(dd,1H),4.05(d,3H),4.01(d,1H),3.88( ddd,2H),3.66–3.60(m,2H),3.59–3.51(m,2H),3.44(dd,1H),2.69(t,1H),2.3 2(s,1H),2.14–2.03(m,2H),1.99–1.79(m,4H),1.65(q,4H),1.34–1.28(m,1H).

[0594] Compound 11:

[0595]

[0596] To a solution of the amine (220.00 mg, 1 eq, 523.10 μmol) and N-ethyl-N-isopropylpropane-2-amine (202.83 mg, 3 eq, 1.5693 mmol) in DCM (15 mL) was added 1H-benzo[d][1,2,3]triazol-1-ol (106.03 mg, 1.5 eq, 784.65 μmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropane-1-amine hydrochloride (150.4 mg, 1.5 eq, 784.65 μmol) and 1-fluorocyclobutane-1-carboxylic acid (61.783 mg, 1 eq, 523.10 μmol) and the resulting mixture was stirred at 25° C. for 2 hours. The resulting mixture was extracted with DCM (3×10 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 60% to 80% gradient, with 10 min; detector, UV 254nm) to obtain an isomeric mixture of the product (200.00 mg, 384.13 μmol, 73%) as an oil.

[0597] The isomeric mixture was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 60:40; flow rate: 1 mL / min; gradient: 0% B to 0% B) to give N-((3R, 4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1s, 4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (65.00 mg, 124.8 μmol, 32.50%) as a solid.

[0598] LCMS: m / z(ES+),[M+H]+=521.20.

[0599] 1H NMR (400MHz, methanol-d4) δ7.92(s,1H),7.62(d,J=16.1Hz,1H),7.49–7.35(m,2H),4.05(d,J=2.0Hz,4H),3.97–3.77(m,2H),3.74–3.58(m,3H),3.49 (q,J=9.0Hz,2H),3.37(s,1H),3.04(d,J=4.0Hz,3H),2.73(s,3H),2.07(d,J=14.9Hz,3H),1.90(dd,J=19.0,9.3Hz,5H),1.65(d,J=9.5Hz,5H).

[0600] Compound 12:

[0601]

[0602] Pyridine (208 mg, 212 μL, 3 equivalents, 2.63 mmol) and triphosgene (130 mg, 0.5 equivalents, 438 μmol) were added to a solution of amine (HCl salt) (400 mg, 1 equivalent, 875 μmol) in DCM (5 mL) at room temperature. The solution was stirred at 25 ° C for 2 hours. The mixture was concentrated under reduced pressure. The residue was redissolved in MeOH (28.0 g, 35.4 mL, 1000 equivalents, 875 mmol) and the resulting solution was heated to 80 ° C and stirred for 30 minutes. The mixture was monitored by LCMS. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 0% to 70% gradient) to obtain a crude product (350 mg, 731 μmol, 83.6%) as a mixture of 4 isomers, which was a solid. The mixture was purified by preparative chiral HPLC (column: CHIRALPAK IC, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: EtOH:DCM=1:1) to give (3R,4S)-3-((((1s,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-4(methylsulfonamido)piperidine-1-carboxylic acid methyl ester (60 mg, 0.13 mmol, 17%) as a solid.

[0603] LCMS: m / z(ES+),[M+H]+=479.25.

[0604] 1H NMR (SNB06-439): (400MHz, methanol-d4) δ7.93(d,J=1.0Hz,1H),7.61(s,1H),7.47(d,J=8.9Hz,1H),7.39(d,J=8.8Hz,1H),4.05(s,3H),3.81(s, 1H),3.65(d,J=22.4Hz,10H),3.03(s,3H),2.69(d,J=12.1Hz,1H),2.19(s,1H),2.10(s,2H),1.90(s,2H),1.80(s,2H),1.74–1.57(m,4H).

[0605] Compound 13:

[0606]

[0607] PEPPSI-Pd (26.6 mg, 0.1 eq., 31.6 μmol) and Cs2CO3 (309 mg, 3 eq., 948 μmol) were added to a solution of amine (150 mg, 1 eq., 316 μmol) and 3-bromopyridazine (101 mg, 2 eq., 632 μmol) in 1,4-dioxane (2 mL). The resulting mixture was stirred at 100 ° C for 3 hours. The reaction was monitored by LCMS. The resulting mixture was extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (EA / PE=2 / 1) to obtain an isomeric mixture of the product (140 mg, 155 μmol, 49.0%) as a solid. The crude product was purified by preparative HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40) to give 1,1,1-trifluoro-N-((3R,4S)-3-((((1s,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)methanesulfonamide (115 mg, 207 μmol, 76.7%) as a solid.

[0608] LCMS: m / z(ES+),[M+H]+=553.25.

[0609] 1H NMR (400MHz, methanol-d4) δ8.07(s,1H),7.51(d,J=1.6Hz,1H),7.46(d,J=8.4Hz,1H),7.25(dd,J=8.4,1 .6Hz,1H),3.89(s,3H),3.87–3.82(m,1H),3.78–3.65(m,2H),3.65–3.54(m,1H),3.51(d,J=9.4Hz, 1H),3.46–3.35(m,2H),3.03(s,3H),2.83–2.60(m,3H),2.46(dq,J=22.5,10.2Hz,2H),2.28–2.04( m,3H),2.02–1.89(m,3H),1.84(d,J=13.4Hz,2H),1.62(q,J=13.5,12.6Hz,3H),1.55–1.33(m,3H).

[0610] Compound 14:

[0611]

[0612] To a solution of amine (HCl salt) (260 mg, 1 eq., 548 μmol) and 1-fluorocyclobutane-1-carboxylic acid (77.7 mg, 1.2 eq., 657 μmol) in DCM (6 mL) was added DIPEA (212 mg, 286 μL, 3 eq., 1.64 mmol) and HOBt (126 mg, 1.5 eq., 822 μmol) and 3-(((ethylimino)methylene)amino)-N,N-dimethylpropane-1-amine hydrochloride (158 mg, 1.5 eq., 822 μmol). The resulting mixture was stirred at 25 °C for 2 hours. The mixture was concentrated under reduced pressure to give a crude product. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 95% gradient in 30 min) to give the crude product (260 mg, 452 μmol, 82.6%) as a mixture of 4 isomers as a solid. The isomer mixture was purified by chiral preparative HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 70:30) to give the desired isomer 1,1,1-trifluoro-N-((3R, 4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1s, 4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (48.4 mg, 83.6 μmol, 17.8%) as a solid.

[0613] LCMS: m / z(ES+),[M+Na]+=597.15.

[0614] 1H NMR (400MHz, chloroform-d) δ7.96 (s, 1H), 7.85 (dd, J = 15.6, 6.4Hz, 1H), 7.57 (d, J = 1.3Hz ,1H),7.42–7.31(m,2H),4.38(dd,J=26.6,13.9Hz,1H),4.09(s,3H),3.99–3.65 (m,5H),3.33–3.02(m,2H),2.97–2.74(m,1H),2.70–2.58(m,2H),2.46(dq,J=22 .9,12.5Hz,4H),2.12–1.89(m,5H),1.76(s,1H),1.68(dd,J=24.1,13.9Hz,4H).

[0615] Compound 15:

[0616]

[0617] To a solution of amine (450 mg, 1 equivalent, 1.07 mmol) and 3-bromo-pyridazine (255 mg, 148 μL, 1.5 equivalents, 1.60 mmol) in 1,4-dioxane (18 mL) was added CsCO (1.05 g, 3 equivalents, 3.21 mmol) and Pd-PEPPSI (89.9 mg, 0.1 equivalents, 107 μmol). After stirring at 100 ° C for 3 hours under a nitrogen atmosphere. The resulting mixture was diluted with H2O (10 mL) and extracted with EtOAc (3x100 mL). The combined organic layer was washed with brine (3x10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: 0.9 g / L NH4HCO3 to water, mobile phase B: ACN, 5% to 95% gradient in 30 min) to give an isomeric mixture of the product (330 mg, 662 μmol, 62%) as a solid.

[0618] The above isomer mixture was purified by chiral HPLC (column: DZ-CHIRALPAK IF-3, 4.6*50 mm, 3.0 μm; mobile phase A: MtBE (0.2% DEA): (MeOH: DCM = 1: 1) = 85: 15; flow rate: 1 mL / min; gradient: 0% B to 0% B) to give N- ((3R, 4S) -3- ((((1s, 4S) -4- (1-methyl-1H-indazol-5-yl) cyclohexyl) oxy) methyl) -1- (pyridazin-3-yl) piperidin-4-yl) methanesulfonamide (69.5 mg, 139 μ mol, 38.5%) as a solid.

[0619] LCMS: m / z(ES+),[M+H]+=499.25.

[0620] 1H NMR(400MHz,DMSO-d6)δ8.52(dd,1H),7.96(d,1H),7.56–7.49(m,2H),7.35–7.21(m,4H),4.01(s,3H),3.88(dt,1H),3.74(dd,2H) ,3.70–3.48(m,4H),3.38(d,1H),3.00(s,3H),2.69–2.58(m,1H),2.14(s,1H),1.95(t,2H),1.85–1.66(m,4H),1.62–1.44(m,4H).

[0621] Compound 16:

[0622]

[0623] 1H-benzo [d] [1,2,3] triazole-1-ol hydrate (163.9 mg, 1.5 equivalents, 1.070 mmol), EDC (205.1 mg, 1.5 equivalents, 1.070 mmol) and DIEA (276.6 mg, 373 μL, 3 equivalents, 2.140 mmol) were added to a solution of amine (300.0 mg, 1 equivalent, 713.3 μmol) and 1-fluorocyclobutane-1-carboxylic acid (101.1 mg, 1.2 equivalents, 856.0 μmol) in DCM (8 mL). The resulting mixture was stirred at 25 ° C for 2 hours. The reaction was monitored by LCMS. The resulting mixture was extracted with dichloromethane (3x30 mL). The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (MeOH / DCM=1 / 12) to give an isomer mixture of the product (190 mg, 324 μmol, 45.4%) as a solid.

[0624] The crude product was purified by preparative chiral HPLC (column: CHIRALPAK IC, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: EtOH:DCM=1:1--HPLC; flow rate: 20 mL / min; gradient: 70% B to 70% B in 11 min) to give N-((3R,4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1s,4S)-4-(1-methyl-1H-benzo[d]imidazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (49.6 mg, 94.4 μmol, 25%) as a solid.

[0625] LCMS: m / z(ES+),[M+H]+=521.30.

[0626] 1H NMR(400MHz, methanol-d4)δ8.06(d,J=3.2Hz,1H),7.54(s,1H),7.46(d,J=8.4Hz, 1H),7.36–7.25(m,1H),3.89(d,J=1.3Hz,4H),3.74(s,1H),3.72–3.58(m,3H ),3.49(q,J=9.1,8.4Hz,2H),3.04(d,J=5.6Hz,3H),2.82–2.64(m,3H),2.48 (d,J=20.9Hz,2H),2.31–1.99(m,3H),2.00–1.75(m,6H),1.75–1.53(m,5H).

[0627] Compound 17:

[0628]

[0629] To a stirred solution of the amine (80 mg, 1 eq., 0.19 mmol) and (R)-tetrahydrofuran-3-carboxylic acid (33 mg, 1.5 eq., 0.29 mmol) in DCM (2 mL) at 25 °C under nitrogen atmosphere were added 1H-benzo[d][1,2,3]triazol-1-ol hydrate (44 mg, 1.5 eq., 0.29 mmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropane-1-amine hydrochloride (55 mg, 1.5 eq., 0.29 mmol) and DIPEA (74 mg, 99 μL, 3 eq., 0.57 mmol) portionwise. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 0% to 100% gradient in 30 min; detector, UV 220 nm) to give an isomeric mixture of the product (90 mg, 0.17 mmol, 91%) as an oil. The crude product (100 mg) was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=30:70) to give N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-((R)-tetrahydrofuran-3-carbonyl)piperidin-4-yl)methanesulfonamide (30 mg, 58 μmol, 30%) as a solid.

[0630] LCMS: m / z(ES+),[M+H]+=519.3.

[0631] 1H NMR (400 MHz, methanol-d4) δ7.93 (d, 1H), 7.61 (d, 1H), 7.47 (dd, 1H), 7.38 (ddd, 1H), 4.05 (d, 3H), 4.01–3.72 (m, 7H), 3.71–3.45 (m, 6H), 3.04 (d, 3H), 2.70 (q, 1H), 2.31–1.97 (m, 5H), 1.95–1.55 (m, 8H).

[0632] Compound 18:

[0633]

[0634] To a solution of amine (80.0 mg, 1 eq., 190 μmol), HOBt (43.7 mg, 1.5 eq., 285 μmol) and EDC (54.7 mg, 1.5 eq., 285 μmol) in DCM (2 mL) was added DIEA (49.2 mg, 66.3 μL, 2 eq., 380 μmol) and cyclopropanecarboxylic acid (24.6 mg, 1.5 eq., 285 μmol). The resulting mixture was stirred at 25 °C for 2 hours. The reaction was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 30% to 60% gradient in 20 min; detector, UV 254 nm) to give an isomeric mixture of the product (90.0 mg, 184 μmol, 96.8%) as an oil. The crude product (95 mg) was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA):(IPA:DCM=1:1)=55:45) to give N-((3R,4S)-1-(cyclopropanecarbonyl)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (37.0 mg, 75.7 μmol, 39%) as a solid.

[0635] LCMS: m / z(ES+),[M+H]+=489.20.

[0636] 1H NMR (400MHz, methanol-d4) δ7.93(d,1H),7.59(d,1H),7.46(d,1H),7.38(dd,1H),4.05(s,4H),3.94–3.77(m,2H),3.68(d,3H ),3.50(dd,1H),3.05(d,3H),2.70(d,1H),2.33–2.02(m,4H),1.97–1.83(m,3H),1.78–1.59(m,5H),0.96–0.77(m,4H).

[0637] Compound 19:

[0638]

[0639] 3-(((ethylimino)methylene)amino)-N,N-dimethylpropane-1-amine hydrochloride (226 mg, 1.5 equivalents, 1.18 mmol) and DIEA (304 mg, 410 μL, 3 equivalents, 2.35 mmol) and HOBt (180 mg, 1.5 equivalents, 1.18 mmol) and 1-fluorocyclobutanecarboxylic acid (111 mg, 1.2 equivalents, 942 μmol) were added to a solution of amine (330 mg, 1 equivalent, 785 μmol) in DCM (14 mL). The resulting mixture was stirred at room temperature for 2 hours. The filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 95% gradient in 30 min; detector, UV 254 nm) to give an isomeric mixture of the product (68 mg, 0.13 mmol, 17%) as a solid.

[0640] The isomeric mixture was purified by chiral HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: MtBE (0.2% DEA): (MeOH: DCM = 1: 1) = 75:25; flow rate: 1 mL / min; gradient: 0% B to 0% B) to give N-((3R, 4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1s, 4S)-4-(1-methyl-1H-benzo[d]imidazol-6-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (7.6 mg, 14 μmol, 27%) as a solid.

[0641] LCMS: m / z(ES+),[M+H]+=521.25.

[0642] 1H NMR (400MHz, methanol-d4) δ8.07(d,1H),7.57(dd,1H),7.49(d,1H),7.26–7.19(m,1H),3.91(d,5H),3.77–3.59(m,3H),3.52(dd ,2H),3.39(d,2H),3.05(d,3H),2.85–2.65(m,3H),2.45(tp,2H),2.32–2.04(m,3H),2.02–1.78(m,5H),1.75–1.53(m,5H).

[0643] Compound 20:

[0644]

[0645] To a stirred solution of the amine (70 mg, 1 eq., 0.17 mmol) in DCM (2 mL) was added triethylamine (51 mg, 3 eq., 0.50 mmol) and acetic anhydride (34 mg, 2 eq., 0.33 mmol) dropwise at 25° C. under nitrogen atmosphere. The residue was purified by preparative TLC (CH2Cl2 / MeOH 10:1) to give an isomeric mixture of the product (70 mg, 0.11 mmol, 64%) as a solid. The crude product (78 mg) was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IH-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 60:40) to give N-((3R, 4S)-1-acetyl-3-((((1s, 4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (23.2 mg, 48.1 μmol, 29%) as a solid.

[0646] LCMS: m / z(ES+),[M+H]+=463.2.

[0647] 1H NMR (400MHz, methanol-d4) δ7.93(s,1H),7.60(d,1H),7.47(d,1H),7.42–7.34(m,1H),4.09–3.94(m,4H),3.82(dd,2H),3.73–3.61(m,3H ),3.52(dd,2H),3.38(d,1H),3.04(d,3H),2.69(t,1H),2.31–2.04(m,6H),1.90(d,3H),1.71(ddd,16.6,9.0Hz,5H),0.11(d,1H).

[0648] Compound 21:

[0649]

[0650] To a stirred solution of the amine (65 mg, 1 eq., 0.15 mmol) and 2-hydroxy-2-methylpropanoic acid (48 mg, 3 eq., 0.46 mmol) in DCM (2 mL) was added 1H-benzo[d][1,2,3]triazol-1-ol hydrate (71 mg, 3 eq., 0.46 mmol), EDC (89 mg, 3 eq., 0.46 mmol), DIEA (0.12 g, 0.16 mL, 6 eq., 0.93 mmol) portionwise at 25° C. under nitrogen atmosphere. The residue was purified by preparative TLC (CH2Cl2 / MeOH 10:1) to give a mixture of isomers of the product (70 mg, 0.14 mmol, 89%) as a solid. The crude product (70 mg) was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40) to give N-((3R,4S)-1-(2-hydroxy-2-methylpropanoyl)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (25.1 mg, 48 μmol, 35%) as a solid.

[0651] LCMS: m / z(ES+),[M+H]+=507.3.

[0652] 1H NMR (400MHz, methanol-d4) δ7.92(s,1H),7.63(s,1H),7.46(d,1H),7.43–7.38(m,1H),4.05(s,4H),3.88(d,1H),3.70–3.59(m,3H),3.51( dd,1H),3.04(s,3H),2.69(t,1H),2.22(s,1H),2.16–2.03(m,2H),1.91(d,4H),1.67(d,4H),1.47(s,6H),1.31(s,2H),0.12(s,1H).

[0653] Compound 22:

[0654]

[0655] To a solution of amine (100 mg, 1 eq., 238 μmol) and TEA (72.2 mg, 99.4 μL, 3 eq., 713 μmol) in DCM (1.5 mL) was added trimethylacetyl chloride (34.4 mg, 35.0 μL, 1.2 eq., 285 μmol). The resulting mixture was stirred at room temperature for 30 minutes. The residue was purified by preparative TLC (EA / PE=1 / 3) to give a crude product as a solid. The filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: 0.9 g / L NH4HCO3 aqueous solution, mobile phase B: ACN, 5% to 95%) to give an isomeric mixture of the product (80 mg, 0.16 mmol, 67%) as a solid.

[0656] The crude product was purified by preparative chiral HPLC (column: DZ-CHIRALPAK IF-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 80:20) to give N-((3R, 4S)-3-((((1s, 4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-pivaloylpiperidin-4-yl)methanesulfonamide (30.7 mg, 60.5 μmol, 38%) as a solid.

[0657] LCMS: m / z(ES+),[M+H]+=505.25.

[0658] 1H NMR(400MHz,DMSO-d6)δ7.93(s,1H),7.55–7.52(m,2H),7.29(dd,2H),4.01(s,3H),3.93(s,2H),3.75–3.68(m,1H) ,3.59(s,1H),3.43(dd,1H),3.38(s,2H),3.30(s,1H),2.96(s,3H),2.64(d,1H),1.96(dd,3H),1.75–1.50(m,8H).

[0659] Compound 23:

[0660]

[0661] To a solution of amine (100 mg, 1 equivalent, 238 μmol) and TEA (120 mg, 166 μL, 5 equivalents, 1.19 mmol) in DCM (1.5 mL) was added triphosgene (42.3 mg, 26 μL, 0.6 equivalents, 143 μmol). The resulting mixture was stirred at 0 ° C for 30 minutes. Under a nitrogen atmosphere at 25 ° C in 1 minute, a solution of azetidine hydrochloride (26.7 mg, 1.2 equivalents, 285 μmol) in DCM (0.2 mL) was added dropwise. The resulting mixture was stirred at room temperature for an additional 1 hour. The crude product was purified by preparative HPLC (XBridge Prep OBD C18 column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 28% B to 48% B, 8 min, 48% B; wavelength: 254 nm). The solvent was evaporated to give an isomeric mixture of the product (60 mg, 0.12 mmol, 50%) as a solid.

[0662] The above isomer mixture was purified by preparative chiral HPLC (CHIRALPAK IE-3, 4.6*50 mm; mobile phase A: MtBE (0.2% DEA): EtOH = 80:20; flow rate: 1 mL / min; gradient: 0% B to 0% B) to give N-((3R, 4S)-1-(azetidine-1-carbonyl)-3-((((1s, 4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (22.4 mg, 43.3 μmol, 36%) as a solid.

[0663] LCMS: m / z(ES+),[M+H]+=504.30.

[0664] 1H NMR(400MHz, chloroform-d)δ7.96(s,1H),7.60(s,1H),7.37(d,2H),6.44(d,1H),4.09(s,3H),4.05–3.97(m,4H),3.80(td,2H),3.70–3.59(m,4H),3 .31(dd,1H),3.17(td,1H),3.00(s,3H),2.67(dq,1H),2.25(p,3H),2. 12–2.02(m,2H),1.95(dtd,1H),1.89–1.73(m,5H),1.68–1.53(m,2H).

[0665] Compound 24:

[0666]

[0667] To a solution of amine (120.0 mg, 1 eq., 252.9 μmol) and 2-fluoropyrimidine (29.76 mg, 1.2 eq., 303.5 μmol) in DMSO (1.2 mL) was added K2CO3 (87.37 mg, 2.5 eq., 632.2 μmol). The resulting mixture was stirred at 100° C. for 2 hours. The reaction was monitored by LCMS. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: NH4HCO3, mobile phase B: ACN, 5% to 100% gradient in 30 minutes and hold 61.5% gradient in 8 minutes) to give 1,1,1-trifluoro-N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyrimidin-2-yl)piperidin-4-yl)methanesulfonamide (117.1 mg, 210 μmol, 83.2%, 99.3% purity) as a solid.

[0668] LCMS: m / z(ES+),[M+H]+=553.25.

[0669] 1H NMR (400MHz, chloroform-d) δ8.34 (d, J = 4.8 Hz, 2H), 7.96 (s, 1H), 7.86 (d, J = 6.4 Hz, 1H), 7.56 (s, 1H), 7.42–7.30 (m, 2H), 6.55 (t, J = 4.7 Hz, 1H), 4.68 (t, J = 13.1 Hz, 2H), 4.07 (s, 3H), 4.01 (s, 1H), 3.91 (t, J = 9.9 Hz,1H),3.78(dd,J=9.8,3.8Hz,1H),3.71–3.62(m,1H),3.36(d,J=13.9Hz,1H),3.29–3.13(m,1H), 2.75–2.58(m,1H),2.52(t,J=5.8Hz,1H),2.19–1.95(m,4H),1.88–1.66(m,4H),1.66–1.52(m,2H).

[0670] Compound 25:

[0671]

[0672] To a solution of amine (120.0 mg, 1 eq., 252.9 μmol) and 2-fluoropyrazine (49.60 mg, 2 eq., 505.8 μmol) in DMSO (1 mL) was added K2CO3 (104.8 mg, 3 eq., 758.6 μmol). The resulting mixture was stirred at 25 °C for 16 hours. The reaction was monitored by LCMS. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water (5 mmol NH4HCO3), mobile phase B: ACN, 5% to 95% gradient, with 30 min; detector, UV 254 nm) to obtain an isomeric mixture of the product (119.4 mg, 213 μmol, 87%) as a solid.

[0673] LCMS: m / z(ES+),[M+H]+=553.3.

[0674] 1H NMR (400MHz, chloroform-d) δ8.18(s,1H),8.11(d,J=2.3Hz,1H),7.93(d,J=0.9Hz,1H),7.89(s,1H),7.82(d,J=6.3H z,1H),7.56(s,1H),7.38–7.29(m,2H),4.33–4.25(m,1H),4.19(d,J=13.8Hz,1H),4.07(s,3H),4.04–3.91(m ,2H),3.76(dd,J=9.8,3.9Hz,1H),3.68(t,J=2.9Hz,1H),3.33(dd,J=13.8,3.4Hz,1H),3.21(ddd,J=13.7,9 .1,4.8Hz,1H),2.71–2.62(m,1H),2.54(t,J=5.0Hz,1H),2.17–2.00(m,4H),1.82–1.69(m,4H),1.59(s,2H).

[0675] Compound 26:

[0676]

[0677] To amine (800mg, 80%wt, 1 equivalent, 1.30mmol) and 3-bromopyridazine (620mg, 3 equivalents, 3.90mmol) and PEPPSI-pd (111mg, 0.1 equivalent, 130μmol) and Cs2CO3 (1.27g, 3 equivalents, 3.90mmol) in DMSO (5mL) solution. The resulting mixture was stirred at 120 ° C for 8 hours. The resulting mixture was extracted with ethyl acetate / water (3x100 mL). The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (EA) to obtain a crude product (220mg, 386μmol, 30%) as a solid. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 5% to 95% gradient in 30 min; detector, UV 220 nm) to give an isomeric mixture of the product (150 mg, 263 μmol, 58%) as a solid. The isomeric mixture was further purified by reverse phase flash chromatography (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: MtBE (0.2% DEA):(EtOH:DCM=1:1)=70:30) to give 1,1,1-trifluoro-N-((3R,4S)-3-((((1s,4S)-4-(7-fluoro-1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)methanesulfonamide (21.9 mg, 38.4 μmol, 23%) as a solid.

[0678] LCMS: m / z(ES+),[M+H]+=571.20.

[0679] 1H NMR (400MHz, methanol-d4) δ8.45 (dd, J=4.2, 1.4Hz, 1H), 7.96 (d, J=2.3Hz, 1H), 7.40–7.29 (m, 3H), 7.05(dd,J=13.5,1.3Hz,1H),4.20(d,J=0.9Hz,3H),4.07(dq,J=11.7,5.9Hz,2H),3.90(dt, J=12.7,6.3Hz,1H),3.76–3.46(m,5H),3.06(q,J=7.3Hz,3H),2.67(t,J=12.0Hz,1H),2.33( s,1H),2.09(d,J=12.8Hz,2H),1.99–1.76(m,4H),1.74–1.55(m,4H),1.31(t,J=7.3Hz,5H).

[0680] Compound 27:

[0681]

[0682] To a solution of amine (80 mg, 1 equivalent, 0.19 mmol) and thiazole-5-carboxylic acid (37 mg, 1.5 equivalents, 0.29 mmol) in DCM (3 mL), HOBt (44 mg, 1.5 equivalents, 0.29 mmol), EDC (55 mg, 1.5 equivalents, 0.29 mmol) and DIEA (74 mg, 99 μ L, 3 equivalents, 0.57 mmol) were added. The resulting mixture was stirred at 25 ° C for 2 hours. The reaction was monitored by LCMS. The resulting mixture was extracted with dichloromethane (3x15 mL). The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 25% to 60% gradient in 30 min; detector, UV 254 nm) to give an isomeric mixture of the product (50 mg, 94 μmol, 49%) as a solid.

[0683] The above isomer mixture (50 mg) was purified by chiral HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 μm; mobile phase A: Hex (0.2% DEA): (EtOH: DCM = 1: 1) = 35:65) to give N-((3R, 4S)-3-((((1s, 4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(thiazole-5-carbonyl)piperidin-4-yl)methanesulfonamide (21.6 mg, 40.6 μmol, 43%) as a solid.

[0684] LCMS: m / z(ES+),[M+H]+=532.20.

[0685] 1H NMR (400MHz, methanol-d4) δ9.10(s,1H),8.25(s,1H),7.93(s,1H),7.54(s,1H),7.45(d,1H),7.32(s,1H),4.04 (s,3H),3.95-3.84(m,4H),3.72–3.44(m,3H),3.04(s,3H),2.62(d,1H),2.17(d,3H),1.97–1.53(m,9H).

[0686] Compound 28:

[0687]

[0688] To a solution of amine (50 mg, 1 eq., 0.12 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (34 mg, 1.5 eq., 0.18 mmol), 3-methyltetrahydrofuran-3-carboxylic acid (31 mg, 2 eq., 0.24 mmol) and 1-hydroxy-1H-benzotriazole (24 mg, 25 μL, 1.5 eq., 0.18 mmol) and diisopropylethylamine (46 mg, 61 μL, 3 eq., 0.36 mmol) in DCM (1 mL) was added. The resulting mixture was stirred at 25° C. for 2 hours. The crude product was purified by reverse phase flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 5% to 95% gradient in 30 min) to give the crude product as a mixture of isomers (60 mg, 0.11 mmol, 95%) as a solid. The isomer mixture was purified by preparative HPLC (column: CHIRALPAK IC, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH) to give the desired isomer N-((3R,4S)-3-((((1s,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-((S)3-methyltetrahydrofuran-3-carbonyl)piperidin-4-yl)methanesulfonamide (10.8 mg, 12%) as a solid.

[0689] LCMS: m / z(ES+),[M+H]+=533.20.

[0690] 1H NMR (400MHz, methanol-d4) δ7.91(d,J=0.9Hz,1H),7.58(s,1H),7.45(d,J=8.7Hz,1H),7.36(d,J=8.8Hz,1H),4.0 8(d,J=8.9Hz,1H),4.03(s,3H),3.83(ddt,J=22.4,8.5,4.6Hz,4H),3.68–3.62(m,2H),3.59(dd,J=9.5,5.3 Hz,1H),3.47(t,J=8.9Hz,1H),3.01(s,3H),2.68(t,J=12.3Hz,1H),2.42(q,J=10.4,9.2Hz,1H),2.25–2.13 (m,1H),2.07(t,J=14.3Hz,2H),2.01–1.75(m,5H),1.64(dd,J=21.1,9.0Hz,4H),1.41(s,3H),0.10(s,1H).

[0691] Compound 29:

[0692]

[0693] To a solution of amine (150.0 mg, 1 eq., 288.1 μmol) and TEA (87.45 mg, 120 μL, 3 eq., 864.3 μmol) in DCM (8 mL) was added methylsulfamoyl chloride (74.65 mg, 2 eq., 576.2 μmol). The resulting mixture was stirred at 25 °C for 16 hours. The residue was purified by preparative TLC (MeOH / DCM=1 / 12) to give a mixture of 4 isomers (120.0 mg, 233.6 μmol, 81.09%) as an oil. The isomers were separated by preparative chiral HPLC (conditions: column: CHIRALPAK IH, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: IPA:DCM=1:1--HPLC; flow rate: 20 mL / min; gradient: 40% B to 40% B, in 16.5 min) to give the desired isomer N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)methanesulfonamide (24.4 mg, 47.3 μmol, 20.3%, 99.6% purity) as a solid.

[0694] LCMS: m / z(ES+),[M+H]+=514.20.

[0695] 1H NMR (400MHz, chloroform-d) δ8.58 (d, J = 4.4 Hz, 1H), 7.94 (s, 1H), 7.60 (s, 1H), 7.36 (d, J = 1.2 Hz, 3H), 7.19 (d, J = 9.4 Hz, 1H), 6.44 (d, J = 4.7 Hz, 1H), 4.30 (d, J = 5.6 Hz, 1H), 4.07 (s, 5H), 3.96–3.80 (m, 3H), 3.74 (d d,J=9.9,3.8Hz,1H),3.67(s,1H),3.55(s,1H),2.79(d,J=5.3Hz,3H),2.74–2.63(m,1H),2.39(s,1H ), 2.19 (s, 1H), 2.06 (t, J = 13.1Hz, 2H), 1.94 (s, 1H), 1.84 (d, J = 11.9Hz, 4H), 1.61 (m, J = 13.7Hz, 2H).

[0696] Compound 30:

[0697]

[0698] To a solution of amine (200.0 mg, 1 eq., 475.6 μmol) and triethylamine (288.7 mg, 6 eq., 2.853 mmol) in DCM (2 mL) was added dimethylsulfamoyl chloride (136.6 mg, 2 eq., 951.1 μmol). The resulting mixture was stirred at 25 °C for 16 hours. The residue was purified by preparative TLC (MeOH / DCM=1 / 12) to give a mixture of 4 isomers (81.0 mg, 153 μmol, 32.4%) as a solid. The isomers were separated by preparative chiral HPLC (column: CHIRALPAK IG, 2*25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: EtOH:DCM=1:1--HPLC; flow rate: 20 mL / min; gradient: 50% B to 50% B, in 23 min) to give N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)dimethylsulfonamide (15.3 mg, 28.9 μmol, 18.9%, 99.8% purity) as a solid.

[0699] LCMS: m / z(ES+),[M+H]+=528.30.

[0700] 1H NMR (400MHz, chloroform-d) δ8.56(d,J=4.4Hz,1H),7.91(s,1H),7.56(d,J=1.3Hz,1H),7.33(d,J=1.2Hz,2H),7.20(dd,J=9.3,4.4Hz, 1H),6.94(dd,J=9.3,1.2Hz,1H),6.38(d,J=5.5Hz,1H),4.23–4.11(m,1H),4.04(s,4H),3.86(dd,J=9.8,7.7Hz,1H),3.78(m, J=9.1,4.2Hz,1H),3.74–3.59(m,3H),3.48(s,1H),3.35(m,J=12.9,8.6,3.6Hz,1H),2.83(s,6H),2.64(m,J=11.6,3.7Hz,1H) ,2.45–2.32(m,1H),2.17–2.00(m,4H),1.95(m,J=9.9,6.3,3.5Hz,1H),1.81(m,J=24.7,13.9,10.7Hz,4H),1.66–1.49(m,2H).

[0701] Compound 58:

[0702]

[0703] To a solution of (3R,4S)-3-(((4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-amine (90.0 mg, 1 eq., 214 μmol) and TEA (130 mg, 179 μL, 6 eq., 1.28 mmol) in DCM (6 mL) was added dimethylcarbamoyl chloride (34.5 mg, 1.5 eq., 321 μmol). The resulting mixture was stirred at 25 °C for 16 hours. The residue was purified by preparative TLC (MeOH / DCM=1 / 12) to give the crude product (85.0 mg, 161 μmol, 75%, 93.0% purity) as an oil. The crude product was purified by preparative chiral HPLC to give the desired compound (20.2 mg, 40.9 μmol, 16.7%, 99.5% purity) as a solid.

[0704] LCMS: m / z (ES+), [M+H]+=492.2

[0705] 1 H NMR (400MHz, DMSO-d6) δ8.50(d,J=4.2Hz,1H),7.95(s,1H),7.60–7.45(m,2H),7.34–7.17(m,3H),5.97(d,J=7.3Hz,1H),4.04(d,J=20.1Hz,6H ), 3.45 (d, J = 5.7Hz, 3H), 2.80 (s, 6H), 2.60 (d, J = 12.5Hz, 1H), 2.18 (s, 1H), 1.93 (d, J = 13.1Hz, 2H), 1.73 (dd, J = 27.7, 13.2Hz, 4H), 1.51 (s, 4H).

[0706] Compounds 59 and 60:

[0707]

[0708] To a solution of N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (50 mg, 1 eq., 0.12 mmol) and tetrahydrofuran-2-carboxylic acid (28 mg, 2 eq., 0.24 mmol) in DCM (1 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (34 mg, 1.5 eq., 0.18 mmol) and 1-hydroxy-1H-benzotriazole (24 mg, 25 μL, 1.5 eq., 0.18 mmol) and diisopropylethylamine (46 mg, 61 μL, 3 eq., 0.36 mmol). The resulting mixture was stirred at 25 °C for 2 hours. The resulting mixture was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography followed by preparative chiral HPLC to give:

[0709] Isomer 1 (12.9 mg, 24.9 μmol, 14%), as a solid.

[0710] LCMS: m / z (ES+), [M+H]+=519.20

[0711] 1H NMR (400MHz, methanol-d4) δ7.93–7.89(m,1H),7.62–7.56(m,1H),7.44(d,J=8.7Hz,1H ),7.37(td,J=9.2,8.7,1.5Hz,1H),4.90(dd,J=8.2,5.4Hz,1H),4.03(d,J=0.9Hz ,3H),4.00–3.53(m,8H),3.52–3.37(m,2H),3.34(s,7H),3.01(d,J=8.7Hz,3H),2 .66(dd,J=12.2,8.9Hz,1H),2.34–2.14(m,2H),2.14–1.51(m,13H),1.29(s,1H).

[0712] Isomer 2 (12.7 mg, 24.5 μmol, 13%), as solid

[0713] LCMS: m / z (ES+), [M+H]+=519.2

[0714] 1H NMR (400MHz, methanol-d4) δ7.93–7.88(m,1H),7.58(d,J=11.1Hz,1H),7.47–7.32(m, 2H),4.94–4.87(m,1H),4.02(d,J=1.1Hz,3H),3.99–3.88(m,2H),3.88–3.77(m, 2H),3.76–3.54(m,5H),3.51–3.38(m,2H),3.01(d,J=8.5Hz,3H),2.74–2.60(m, 1H),2.33–2.14(m,2H),2.05(td,J=13.4,12.7,4.8Hz,3H),1.97–1.55(m,11H).

[0715] Compound 61:

[0716]

[0717] To a stirred solution of N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (100 mg, 1 eq, 238 μmol) in acetonitrile (2 mL) at 25 °C under a hydrogen / nitrogen atmosphere were added dropwise 2-chloro-1-(piperidin-1-yl)ethan-1-one (38.4 mg, 1 eq, 238 μmol), N-ethyl-N-isopropylpropan-2-amine (36.9 mg, 1.2 eq, 285 μmol) and potassium iodide (39.5 mg, 1 eq, 238 μmol) were added portionwise. The residue was purified by preparative TLC and then by preparative chiral HPLC to give the product (23.5 mg, 42.2 μmol, 21%, 97.9% purity) as a solid.

[0718] LCMS: m / z (ES+), [M+H]+=546.4

[0719] 1 H NMR (400MHz, methanol-d4) δ7.93(d,1H),7.60(d,1H),7.47(d,1H),7.38(dd,1H),4.05(s,3H),3.71–3.56(m,6H),3.51–3.44(m,1H),3.42–3. 36(m,1H),3.28(s,1H),3.16(d,1H),3.01(s,3H),2.75–2.51(m,5H),2.26(d,1H),2.09(d,2H),1.93–1.81(m,4H),1.69–1.48(m,11H).

[0720] Compound 62:

[0721]

[0722] To a solution of N-((3R,4S)-3-((((1s,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (80 mg, 1 eq., 0.19 mmol) and HOBt (44 mg, 1.5 eq., 0.29 mmol) in DCM (2 mL) was added EDC (55 mg, 1.5 eq., 0.29 mmol) and DIEA (74 mg, 99 μL, 3 eq., 0.57 mmol) and (S)-tetrahydrofuran-3-carboxylic acid (33 mg, 1.5 eq., 0.29 mmol). After stirring at 25 °C under nitrogen atmosphere for 8 h, the resulting mixture was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography followed by preparative chiral HPLC to give the desired product (16 mg, 31 μmol, 16%, 99% purity) as a solid.

[0723] LCMS: m / z (ES+), [M+H]+=519.3

[0724] 1 H NMR(400MHz, methanol-d4)δ7.93(s,1H),7.60(d,1H),7.47(d,1H),7.38(dd,1H),4.09–4.02(m,3H),4.0 0–3.73(m,7H),3.70–3.44(m,6H),3.04(d,3H),2.70(d,1H),2.32–1.99(m,5H),1.97–1.57(m,8H).

[0725] Compounds 63 and 64:

[0726]

[0727] To a solution of N-((3R,4S)-3-(((4-(1-methyl-1H-benzo[d]imidazol-6-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (130 mg, 1 eq., 309 μmol) and pyridin-2-yl trifluoromethanesulfonate (84.3 mg, 1.2 eq., 371 μmol) in DMSO (5 mL) was added TEA (93.8 mg, 129 μL, 3 eq., 927 μmol). After stirring at 120 °C for 3 h under nitrogen atmosphere, the resulting mixture was diluted with H2O (50 mL) and extracted with EtOAc (3x20 mL). The combined organic layers were washed with brine (1x50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.

[0728] The crude product was purified by reverse phase flash chromatography to give:

[0729] Isomer 1 (7.2 mg, 14 μmol, 40%) was obtained as a solid.

[0730] LCMS: m / z (ES+), [M+H]+=498

[0731] 1 H NMR(400MHz, methanol-d4)δ8.10–8.02(m,2H),7.61–7.48(m,2H),7.46(d,1H),7 .19(dd,,1H),6.91-6.84(m,1H),6.70-6.59(m,1H),3.89(s,5H),3.82–3.4 3(m,6H),3.06(s,3H),2.81–2.68(m,1H),2.38-2.29(m,1H),2.10(d,2H),2 .01-1.85(m,4H),1.76-1.58(m,4H),1.41–1.23(m,2H),0.96–0.86(m,1H).

[0732] Isomer 2 (1 mg, 2 μmol, 20%) as a solid.

[0733] LCMS: m / z (ES+), [M+H]+=498

[0734] 1H NMR (400MHz, methanol-d4) δ8.08(d,1H),7.57(t,1H),7.41(s,1H),7.19(d,1H),6.89(d,1H),6.72–6.63(m,1H),4.64(s,2H),3.89(s,3H),3.75(dd, 2H),3.65–3.54(m,3H),3.05(s,2H),2.71(s,1H),2.21(s,3H),1.98(d ,1H),1.87(d,1H),1.64(d,2H),1.43(s,2H),1.31(s,3H),0.92(s,1H).

[0735] Compounds 65 and 66:

[0736]

[0737] To a solution of N-((3R,4S)-3-(((4-(1-methyl-1H-indazol-6-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (100 mg, 1 eq., 238 μmol) and pyridin-2-yl trifluoromethanesulfonate (59.4 mg, 1.1 eq., 262 μmol) in DMSO (5 mL) was added TEA (72.2 mg, 99.4 μL, 3 eq., 713 μmol). After stirring at 120 °C for 3 h under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography and then by chiral HPLC to give:

[0738] Isomer 1:

[0739] LCMS: m / z (ES+), [M+H]+=498

[0740] 1 H NMR (400 MHz, CHLOROFORM-d) δ8.19 (dd, 1H), 7.92 (s, 1H), 7.63 (d, 1H), 7.53 (s, 1H), 7.40 (s, 1H), 7.04 (d, 1H), 6.78–6.64 (m, 2H), 6.57 (d, 1H), 4.10 (s, 3H), 4.05 (dd, 1H), 3.96 (t, 2H) ,3.87(s,1H),3.73(d,1H),3.67(s,1H),3.55(s,1H),3.33(s,1H),3.03(s,3H),2.69( d,1H),2.41(s,1H),2.10(d,3H),2.03(s,1H),1.83(d,4H),1.28(s,1H),0.09(s,7H).

[0741] Isomer 2 (5.7 mg, 11 μmol, 38%) was obtained as a solid.

[0742] LCMS: m / z (ES+), [M+H]+=498

[0743] 1 H NMR (400MHz, methanol-d4) δ8.08(dd,1H),7.92(d,1H),7.65(d,1H),7.62-7.55(m,1H),7.48(s,1H),7.36(s,1H),7.08(dd,1H),6. 90(d,1H),6.67(dd,1H),4.04(s,3H),3.89–3.79(m,2H),3.75(dd,1H),3.69–3.47(m,4H),3.40(dd,,1H),3.05(s,3H),2.70

[0744] (t,1H),2.22(d,3H),1.99(d,2H),1.87(q,2H),1.74–1.53(m,2H),1.44(q,2H),1.31(s,1H).

[0745] Example 2: Human OX2R IP1 Assay

[0746] T-Rex CHO cells stably overexpressing human orexin-2 receptor (OX2R) were induced overnight with 1 μg / mL doxycycline in T225 flasks. 24 hours after induction, cells were lifted with accutase and plated at 30,000 cells / well in 384-well proxy plates. Cells were then treated with different test compounds for 1 hour at 37°C in 1X stimulation buffer at pH 7.4, which contained 10mM Hepes, 1mM CaCl2, 0.5mM MgCl2, 4.2mMKCl, 146mM NaCl, 5.5mM glucose, and 50mM LiCl. After incubation, the reaction was terminated by adding a detection mixture consisting of IP1-d2 and anti-IP1-cryptate diluted in lysis buffer and 1X stimulation buffer. The plate was incubated at room temperature for 1 hour, and then The inositol phosphate levels were measured by reading in a multimode plate reader.

[0747] Cisbio IP1 is a cell-based functional assay that quantifies the accumulation of inositol monophosphate (IP), a metabolite released as a result of activation of the orexin 2 receptor via the phospholipase C-Gq signaling pathway. This is a competitive immunoassay in which IP1 produced by cells upon receptor activation competes with an IP1 analog (acceptor) coupled to a d2 fluorophore for binding to an anti-IP1 monoclonal antibody (donor) labeled with Eu cryptate. The HTRF-FRET-based signal measured is inversely proportional to the concentration of IP1 produced.

[0748] The EC reported in Table 2 were obtained according to the human OX2R IP1 assay described above. 50 Values. Data are mean EC 50 Values ​​± SEM.

[0749] Table 2.

[0750]

[0751]

[0752]

[0753]

[0754]

[0755]

[0756]

[0757]

[0758]

[0759]

[0760]

[0761]

[0762] ***EC 50 <1nM

[0763] **EC 50 1-10nM

[0764] *EC 50 >10nM

[0765] While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as encompassed by the appended claims.

Claims

1. A compound of formula I or a pharmaceutically acceptable salt thereof: in: Ring A is fused to ring B; Ring A is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium; Ring B is selected from C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 The group consisting of aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium; X is N or CH; Y is S(=O)2, C(=O) or S(=O)(=NR e ); R e Selected from the group consisting of H, C1-C3 alkyl or C3-C5 cycloalkyl; E is selected from the group consisting of: NR a R b 、C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl, and C1-C3 alkylene-(5- to 7-membered heteroaryl), wherein the C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl) is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution; R a and R b Each independently selected from the group consisting of H, C1-C3 alkyl, C3-C5 cycloalkyl and 4- to 7-membered heterocyclyl; wherein the C1-C3 alkyl, C3-C5 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxy; Or, alternatively, R a and R b Together with the N atom to which they are attached, they form a 4- to 7-membered heterocyclyl or a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , C1-C3 alkyl, C1-C3 alkoxy or C1-C3 alkyl substituted by 1-3 halogens; R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 Aryl), C(=O)-(CR c R d ) n -(5- to 10-membered heteroaryl), C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclic group), (CR c R d ) n -(C6-C 10 Aryl) and (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 Aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium; R c and R d Each is independently H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogens or deuterium; n is 0, 1, or 2; Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium; Or, alternatively, R3 and R6 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens; Or, alternatively, R4 and R5 together form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted by one or more halogens; m is 0 or 1; p is 0, 1, 2, 3 or 4; and Each R9 is independently selected from the group consisting of deuterium, halogen, hydroxyl and cyano.

2. The compound according to claim 1, wherein Ring A is selected from the group consisting of: C3-C8 cycloalkyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

3. The compound according to claim 1, wherein Ring A is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

4. The compound according to claim 1, wherein Ring A is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group and C6-C 10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

5. The compound according to claim 1, wherein Ring A is selected from the group consisting of: C6-C 10 Aryl and 5- to 7-membered heteroaryl, wherein the C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

6. The compound according to claim 1, wherein Ring A is selected from the group consisting of: C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

7. The compound according to claim 1, wherein Ring A is selected from the group consisting of C3-C8 cycloalkyl and C6-C 10 Aryl, wherein the C3-C8 cycloalkyl or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

8. The compound according to claim 1, wherein Ring A is selected from the group consisting of a 4- to 7-membered heterocyclic group and a C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

9. The compound according to claim 1, wherein Ring A is selected from the group consisting of a 4- to 7-membered heterocyclyl and a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

10. The compound according to claim 1, wherein Ring A is a C3-C8 cycloalkyl group, wherein the C3-C8 cycloalkyl group is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

11. The compound according to claim 1, wherein Ring A is a 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

12. The compound according to claim 1, wherein Ring A is C6-C 10 Aryl, wherein the C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

13. The compound according to claim 1, wherein Ring A is a 5- to 7-membered heteroaryl, wherein the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

14. The compound according to claim 1, wherein Ring B is selected from the group consisting of 4- to 7-membered heterocyclic groups, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclic group, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

15. The compound according to claim 1, wherein Ring B is selected from the group consisting of: C3-C8 cycloalkyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

16. The compound according to claim 1, wherein Ring B is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

17. The compound according to claim 1, wherein Ring B is selected from the group consisting of C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group and C6-C 10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

18. The compound according to claim 1, wherein Ring B is selected from the group consisting of: C6-C 10 Aryl and 5- to 7-membered heteroaryl, wherein the C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

19. The compound according to claim 1, wherein Ring B is selected from the group consisting of C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

20. The compound according to claim 1, wherein Ring B is selected from the group consisting of C3-C8 cycloalkyl and C6-C 10 Aryl, wherein the C3-C8 cycloalkyl or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

21. The compound according to claim 1, wherein Ring B is selected from the group consisting of a 4- to 7-membered heterocyclic group and a C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

22. The compound according to claim 1, wherein Ring B is selected from the group consisting of a 4- to 7-membered heterocyclyl and a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

23. The compound according to claim 1, wherein Ring B is a C3-C8 cycloalkyl group, wherein the C3-C8 cycloalkyl group is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

24. The compound according to claim 1, wherein Ring B is a 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

25. The compound according to claim 1, wherein Ring B is C6-C 10 Aryl, wherein the C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

26. The compound according to claim 1, wherein Ring B is a 5- to 7-membered heteroaryl, wherein the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

27. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of a 4- to 7-membered heterocyclic group, a C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclic group, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

28. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of C3-C8 cycloalkyl, C6-C 10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

29. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of a C3-C8 cycloalkyl group, a 4- to 7-membered heterocyclyl group, and a 5- to 7-membered heteroaryl group, wherein the C3-C8 cycloalkyl group, the 4- to 7-membered heterocyclyl group, or the 5- to 7-membered heteroaryl group is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl group, or C1-C3 alkyl group substituted with one or more halogen or deuterium.

30. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of a C3-C8 cycloalkyl group, a 4- to 7-membered heterocyclic group, and a C6-C 10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

31. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of: C6-C 10 Aryl and 5- to 7-membered heteroaryl, wherein the C6-C 10 The aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

32. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of a C3-C8 cycloalkyl group and a 4- to 7-membered heterocyclyl group, wherein the C3-C8 cycloalkyl group or the 4- to 7-membered heterocyclyl group is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl group, or C1-C3 alkyl group substituted with one or more halogen or deuterium.

33. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of C3-C8 cycloalkyl and C6-C 10 Aryl, wherein the C3-C8 cycloalkyl or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

34. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of a 4- to 7-membered heterocyclic group and a C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group or C6-C 10 Aryl is unsubstituted or substituted by one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

35. The compound according to claim 1, wherein Ring A and Ring B are each independently selected from the group consisting of a 4- to 7-membered heterocyclyl and a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 substituted with one or more halogen or deuterium. C3 alkyl substituted.

36. The compound according to claim 1, wherein Ring A is a 5- to 7-membered heteroaryl and Ring B is C6-C 10 aryl, wherein the 5- to 7-membered heteroaryl and C6-C 10 The aryl groups are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

37. The compound according to claim 1, wherein Ring A is a 5- to 7-membered heteroaryl and Ring B is a 5- to 7-membered heteroaryl, wherein each 5- to 7-membered heteroaryl is independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

38. The compound according to claim 1, wherein Ring A is a 4- to 7-membered heterocyclic group and Ring B is a C6-C 10 Aryl, wherein the 4- to 7-membered heterocyclic group and C6-C 10 The aryl groups are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

39. The compound according to claim 1, wherein Ring A is a 4- to 7-membered heterocyclyl and Ring B is a 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl and the 5- to 7-membered heteroaryl are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

40. The compound according to claim 1, wherein Ring A is C3-C8 cycloalkyl and Ring B is C6-C 10 Aryl, wherein the C3-C8 cycloalkyl and C6-C 10 The aryl groups are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

41. The compound according to claim 1, wherein Ring A is C3-C8 cycloalkyl and Ring B is 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl and 5- to 7-membered heteroaryl are each independently unsubstituted or substituted with one or more halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

42. The compound according to claim 1, wherein is selected from the group consisting of benzimidazolyl, 1H-pyrazolo[3,4-c]pyridinyl, imidazo[1,5-a]pyridinyl, indolyl, isoindolyl, indolyl, indazolyl, isoindazolyl, benzothiazolyl, purinyl, benzofuranyl, benzisoxazolyl, benzisothiazolyl, isobenzofuranyl, benzothiofuranyl, indolenolyl, pyrano[3,4-b]-pyrrolyl, indolooxazinyl, benzoxazolyl, o-aminobenzoyl and indolizinyl, wherein the benzimidazolyl, 1H-pyrazolo[3,4-c]pyridinyl, imidazo[1,5-a]pyridinyl, indolyl, isoindolyl, indolyl, benzothiazolyl, benzofuranyl, benzisoxazolyl, benzisothiazolyl, isobenzofuranyl, benzothiofuranyl, indolenolyl, pyrano[3,4-b]-pyrrolyl, indolooxazinyl, benzoxazolyl, o-aminobenzoyl and indolizinyl 5-a] pyridyl, indolyl, isoindolyl, indolyl, indazolyl, isoindazolyl, benzothiazolyl, purinyl, benzofuranyl, benzisoxazolyl, benzisothiazolyl, isobenzofuranyl, benzothiofuranyl, indolenolyl, pyrano[3,4-b]-pyrrolyl, indoloxazinyl, benzoxazolyl, o-aminobenzoyl and indolizinyl are unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

43. The compound according to claim 1, wherein It is a benzimidazolyl group, wherein the benzimidazolyl group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

44. The compound according to claim 1, wherein is 1H-pyrazolo[3,4-c]pyridinyl, wherein the 1H-pyrazolo[3,4-c]pyridinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

45. The compound according to claim 1, wherein It is imidazo[1,5-a]pyridinyl, wherein the imidazo[1,5-a]pyridinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

46. ​​The compound according to claim 1, wherein is indolyl, wherein the indolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

47. The compound according to claim 1, wherein is isoindole, wherein the isoindole is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

48. The compound according to claim 1, wherein It is indolinyl, wherein the indolinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

49. The compound according to claim 1, wherein is indazolyl, wherein the indazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

50. The compound according to claim 1, wherein is isoindazolyl, wherein the isoindazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

51. The compound according to claim 1, wherein is benzothiazolyl, wherein the benzothiazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

52. The compound according to claim 1, wherein is a purinyl group, wherein the purinyl group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

53. The compound according to claim 1, wherein is benzofuranyl, wherein the benzofuranyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

54. The compound according to claim 1, wherein is benzisoxazolyl, wherein the benzisoxazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

55. The compound according to claim 1, wherein is a benzisothiazolyl group, wherein the benzisothiazolyl group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

56. The compound according to claim 1, wherein isobenzofuranyl, wherein the isobenzofuranyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

57. The compound according to claim 1, wherein is benzothiofuranyl, wherein the benzothiofuranyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

58. The compound according to claim 1, wherein is an indolenine group, wherein the indolenine group is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

59. The compound according to claim 1, wherein It is pyrano[3,4-b]-pyrrolyl, wherein the pyrano[3,4-b]-pyrrolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

60. The compound according to claim 1, wherein is indoloxazinyl, wherein the indoloxazinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

61. The compound according to claim 1, wherein is benzoxazolyl, wherein the benzoxazolyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

62. The compound according to claim 1, wherein is anthranilyl, wherein the anthranilyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

63. The compound according to claim 1, wherein is indolizinyl, wherein the indolizinyl is unsubstituted or substituted by 1-3 substituents selected from halogen, hydroxy, C1-C3 alkoxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by 1-3 halogen or deuterium atoms.

64. A compound according to any one of claims 1 to 63, wherein p is 0.

65. A compound according to any one of claims 1 to 63, wherein p is 1.

66. A compound according to any one of claims 1 to 63, wherein p is 2.

67. A compound according to any one of claims 1 to 63, wherein p is 3.

68. A compound according to any one of claims 1 to 63, wherein p is 4.

69. A compound according to any one of claims 1 to 63, wherein p is 0, 1 or 2.

70. A compound according to any one of claims 1 to 63, wherein p is 0 or 1.

71. A compound according to any one of claims 1 to 70, wherein E is NR a R b .

72. A compound according to any one of claims 1 to 70, wherein E is C1-C3 alkylene-NR a R b .

73. A compound according to any one of claims 1 to 70, wherein E is an unsubstituted C1-C3 alkyl group, an unsubstituted C2-C4 alkenyl group or an unsubstituted C2-C4 alkynyl group.

74. A compound according to any one of claims 1 to 70, wherein E is C1-C3 alkyl, C2-C4 alkenyl or C2-C4 alkynyl substituted by one or more halogen, hydroxy, C1-C3 alkyl or C1-C3 alkoxy.

75. A compound according to any one of claims 1 to 70, wherein E is an unsubstituted C1-C3 alkyl group.

76. A compound according to any one of claims 1 to 70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkyl substituted with C1-C3 alkoxy.

77. A compound according to any one of claims 1 to 70, wherein E is an unsubstituted C3-C8 cycloalkyl group.

78. A compound according to any one of claims 1 to 70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C3-C8 cycloalkyl.

79. A compound according to any one of claims 1 to 70, wherein E is unsubstituted C1-C3 alkylene-(C3-C8 cycloalkyl).

80. A compound according to any one of claims 1 to 70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(C3-C8 cycloalkyl).

81. A compound according to any one of claims 1 to 70, wherein E is an unsubstituted 4- to 10-membered heterocyclic group.

82. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, a 4- to 10-membered heterocyclic group substituted with a C1-C3 alkyl group or a C1-C3 alkoxy group.

83. A compound according to any one of claims 1-70, wherein E is unsubstituted C1-C3 alkylene-(4- to 10-membered heterocyclic group).

84. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(4- to 10-membered heterocyclic group).

85. A compound according to any one of claims 1-70, wherein E is unsubstituted C6-C 10 Aryl.

86. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C6-C substituted by C1-C3 alkyl or C1-C3 alkoxy 10 Aryl.

87. A compound according to any one of claims 1-70, wherein E is an unsubstituted C1-C3 alkylene-(C6-C 10 aryl).

88. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(C6-C 10 aryl).

89. A compound according to any one of claims 1 to 70, wherein E is an unsubstituted 5- to 7-membered heteroaryl group.

90. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted 5- to 7-membered heteroaryl.

91. A compound according to any one of claims 1-70, wherein E is unsubstituted C1-C3 alkylene-(5- to 7-membered heteroaryl).

92. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted C1-C3 alkylene-(5- to 7-membered heteroaryl).

93. A compound according to any one of claims 1-70, wherein E is C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl), wherein the C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl) is unsubstituted or replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution.

94. A compound according to any one of claims 1-70, wherein E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl), wherein the C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl or C1-C3 alkylene-(4- to 10-membered heterocyclyl) is unsubstituted or replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution.

95. A compound according to any one of claims 1-70, wherein E is C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl), wherein the C1-C3 alkyl, C3-C8 cycloalkyl C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl) is unsubstituted or substituted by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substitution.

96. A compound according to any one of claims 1-70, wherein E is methyl.

97. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted methyl.

98. A compound according to any one of claims 1-70, wherein E is CF3.

99. A compound according to any one of claims 1-70, wherein E is CHF2.

100. A compound according to any one of claims 1-70, wherein E is CH2F.

101. A compound according to any one of claims 1-70, wherein E is NH(CH3).

102. A compound according to any one of claims 1-70, wherein E is N(CH3)2.

103. A compound according to any one of claims 1-70, wherein E is C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5- to 7-membered heteroaryl, or C1-C3 alkylene-(5- to 7-membered heteroaryl).

104. A compound according to any one of claims 1-70, wherein E is unsubstituted C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl).

105. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C6-C substituted by C1-C3 alkyl or C1-C3 alkoxy 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl).

106. A compound according to any one of claims 1-70, wherein E is a 5- to 7-membered heteroaryl group or a C1-C3 alkylene-(5- to 7-membered heteroaryl group).

107. A compound according to any one of claims 1-70, wherein E is unsubstituted 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl).

108. A compound according to any one of claims 1-70, wherein E is replaced by one or more halogen, hydroxyl, NR c R d , CF3, CHF2, CH2F, C1-C3 alkyl or C1-C3 alkoxy substituted 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl).

109. A compound according to any one of claims 1 to 108, wherein Y is S(=O)2.

110. A compound according to any one of claims 1 to 108, wherein Y is C(=O).

111. A compound according to any one of claims 1 to 108, wherein Y is S(=O)(=NR e ).

112. A compound according to any one of claims 1 to 111, wherein X is N.

113. A compound according to any one of claims 1-111, wherein X is CH.

114. A compound according to any one of claims 1 to 113, wherein R1 is selected from the group consisting of: C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy, C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 aryl) and C(═O)-(CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

115. A compound according to any one of claims 1 to 113, wherein R1 is selected from the group consisting of C(=O)-C1-C4 alkyl, C(=O)-C1-C4 alkoxy and C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, wherein the C1-C4 alkyl, C1-C4 alkoxy or C3-C8 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

116. A compound according to any one of claims 1 to 113, wherein R1 is selected from the group consisting of: C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), C(=O)-(CR c R d ) n -(C6-C 10 aryl) and C(═O)-(CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 4- to 7-membered heterocyclyl, C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

117. A compound according to any one of claims 1 to 113, wherein R1 is C(=O)-C1-C4 alkyl, wherein the C1-C4 alkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

118. A compound according to any one of claims 1 to 113, wherein R1 is C(=O)-C1-C4 alkoxy, wherein the C1-C4 alkoxy is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

119. A compound according to any one of claims 1 to 113, wherein R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

120. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

121. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

122. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

123. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heterocyclyl), wherein the 5- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

124. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 6-membered heterocyclyl), wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

125. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), wherein the 5-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

126. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), wherein the 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

127. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6 aryl), wherein the C6 aryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

128. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C8 aryl), wherein the C8 aryl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

129. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C 10 aryl), wherein the C 10 Aryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted with one or more halogen or deuterium.

130. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

131. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

132. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

133. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(7-membered heteroaryl), wherein the 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

134. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl or C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

135. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

136. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

137. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -C3-C5 cycloalkyl, wherein the C3-C5 cycloalkyl is unsubstituted or substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl or C1-C3 alkyl substituted by one or more halogen or deuterium.

138. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(5- to 6-membered heterocyclyl), wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

139. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), wherein the 5-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

140. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), wherein the 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

141. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl group is unsubstituted.

142. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

143. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 0.

144. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium, and further wherein n is 0.

145. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 1.

146. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 Aryl) or (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the C6-C 10 The aryl or 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

147. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl groups are unsubstituted.

148. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 The aryl group is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

149. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted, and further wherein n is zero.

150. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 The aryl group is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

151. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 Aryl is unsubstituted, and further wherein n is 1.

152. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), wherein the C6-C 10 The aryl group is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

153. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted.

154. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

155. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 0.

156. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

157. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted, and further wherein n is 1.

158. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

159. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted.

160. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

161. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted, and further wherein n is 0.

162. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

163. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted, and further wherein n is 1.

164. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(5- to 7-membered heteroaryl), wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

165. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is unsubstituted.

166. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

167. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is unsubstituted, and further wherein n is 0.

168. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

169. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is unsubstituted, and further wherein n is 1.

170. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(phenyl) or (CR c R d ) n -(6-membered heteroaryl), wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

171. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted.

172. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

173. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted, and further wherein n is 0.

174. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

175. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted, and further wherein n is 1.

176. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

177. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted.

178. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is substituted by one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted by one or more halogen or deuterium.

179. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted, and further wherein n is 0.

180. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 0.

181. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted, and further wherein n is 1.

182. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5-membered heteroaryl), wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxy, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium, and further wherein n is 1.

183. A compound according to any one of claims 1-182, wherein Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.

184. A compound according to any one of claims 1-182, wherein Each of R2, R3, R4, R5, R6, R7 and R8 is independently H, halogen or unsubstituted C1-C3 alkyl.

185. A compound according to any one of claims 1-182, wherein Each of R2, R3, R4, R5, R6, R7 and R8 is independently H or halogen.

186. A compound according to any one of claims 1-182, wherein Each of R2, R3, R4, R5, R6, R7 and R8 is independently H or fluoro.

187. A compound according to any one of claims 1-182, wherein Each of R2, R3, R4, R5, R6, R7 and R8 is independently H or C1-C3 alkyl.

188. A compound according to any one of claims 1-182, wherein Each of R2, R3, R4, R5, R6, R7 and R8 is H.

189. A compound according to any one of claims 1-182, wherein R3 and R6 together form an unsubstituted C1-C3 alkylene group or a C1-C3 alkylene group substituted by one or more halogen groups.

190. A compound according to any one of claims 1-182, wherein R4 and R5 together form an unsubstituted C1-C3 alkylene group or a C1-C3 alkylene group substituted by one or more halogen groups.

191. A compound according to any one of claims 1-113, wherein R1 is C(═O)-C1-C4 alkyl, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

192. A compound according to any one of claims 1-113, wherein R1 is C(═O)-C1-C4 alkyl, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl.

193. A compound according to any one of claims 1-113, wherein R1 is C(═O)-C1-C4 alkoxy, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

194. A compound according to any one of claims 1-113, wherein R1 is C(═O)-C1-C4 alkoxy, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl.

195. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

196. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, and each of R2, R3, R4, R5, R6, R7 and R8 is H or unsubstituted C1-C3 alkyl.

197. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

198. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

199. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

200. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

201. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

202. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

203. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

204. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

205. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

206. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

207. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

208. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6-C 10 aryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

209. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6-C 10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

210. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6-C 10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

211. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6 aryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

212. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

213. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

214. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

215. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

216. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

217. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

218. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

219. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

220. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

221. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

222. A compound according to any one of claims 1-113, wherein R1 is C(=O)-(CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

223. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

224. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

225. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

226. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

227. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

228. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

229. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

230. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

231. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

232. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

233. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

234. A compound according to any one of claims 1-113, wherein R1 is C(=O)-O-(CR c R d ) n -(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

235. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 10-membered heteroaryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

236. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(5- to 7-membered heteroaryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

237. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

238. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

239. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

240. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6-C 10 aryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

241. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6 aryl), and each of R2, R3, R4, R5, R6, R7 and R8 is H.

242. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

243. A compound according to any one of claims 1-113, wherein R1 is (CR c R d ) n -(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7 and R8 is H.

244. A compound according to any one of claims 1-113, wherein R1 is 3-pyridazinyl.

245. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:

246. A pharmaceutical composition comprising a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

247. A method of treating narcolepsy in a subject in need thereof, the method comprising administering to the subject a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, or a composition according to claim 246.

248. A method of treating cataplexy in a subject in need thereof, the method comprising administering to the subject a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, or a composition according to claim 246.

249. Use of a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, or a composition according to claim 246 for the manufacture of a medicament for narcolepsy.

250. Use of a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, or a composition according to claim 246 for the manufacture of a medicament for cataplexy.

251. Use of a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, or a composition according to claim 246, for use in a method of treating narcolepsy in a subject in need thereof.

252. Use of a compound according to any one of claims 1-245 or a pharmaceutically acceptable salt thereof, or a composition according to claim 246, for use in a method of treating cataplexy in a subject in need thereof.

Images